

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12385023
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Wang; Yi et al.

CRISPR-Cas system for clostridium genome engineering and recombinant strains produced thereof

Abstract

A system for modifying the genome of *Clostridium* strains is provided based on a modified endogenous CRISPR array. The application also describes *Clostridium* strains modified for enhanced butanol production wherein the modified strains are produced using the novel CRISPR-Cas system.

Inventors:	Wang; Yi (Auburn, AL), Zhang; Jie (Auburn, AL)
Applicant:	AUBURN UNIVERSITY (Auburn, AL)
Family ID:	1000008750338
Assignee:	AUBURN UNIVERSITY (Auburn, AL)
Appl. No.:	17/469386
Filed:	September 08, 2021

Prior Publication Data

Document Identifier	Publication Date
US 20210403889 A1	Dec. 30, 2021

Related U.S. Application Data

division parent-doc US 16811733 20200306 US 11142751 child-doc US 17469386
us-provisional-application US 62815198 20190307

Publication Classification

Int. Cl.: C12N9/22 (20060101); C12N1/20 (20060101); C12N15/63 (20060101); C12R1/145 (20060101)

U.S. Cl.:

CPC C12N9/22 (20130101); C12N15/63 (20130101); C12N1/205 (20210501); C12N2310/20 (20170501); C12R2001/145 (20210501)

Field of Classification Search

CPC: C12N (15/63); C12N (2310/20); C12R (2001/145)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
9284580	12/2015	Yang et al.	N/A	N/A
2009/0111154	12/2008	Liao et al.	N/A	N/A
2011/0027845	12/2010	Lee et al.	N/A	N/A
2011/0236941	12/2010	Koepke et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2007/332240	12/2007	AU	N/A
2008/052973	12/2007	WO	N/A
2012/045022	12/2011	WO	N/A
2015/159086	12/2014	WO	N/A
2015/159087	12/2014	WO	N/A

OTHER PUBLICATIONS

Keis, S., Shaheen, R., Jones, D. T., Emended descriptions of *Clostridium acetobutylicum* and *Clostridium beijerinckii*, and descriptions of *Clostridium saccharoperbutylacetonicum* sp. nov. and *Clostridium saccharobutylicum* sp. nov. International Journal of Systematic and Evolutionary Microbiology 2001, 51, 2095-2103. cited by applicant

Lee, S. Y., Park, J. H., Jang, S. H., Nielsen, L. K., et al., Fermentative butanol production by clostridia. Biotechnology and Bioengineering 2008, 101, 209-228. cited by applicant

Lee, J., Jang, Y.-S., Han, M.-J., Kim, J. Y., Lee, S. Y., Deciphering *Clostridium tyrobutyricum* metabolism based on the whole-genome sequence and proteome analyses. mBio 2016, 7(3):e00743-16. cited by applicant

Zhang, J., Zong, W., Hong, W., Zhang, Z.-T., Wang, Y., Exploiting endogenous CRISPR-Cas system for multiplex genome editing in *Clostridium tyrobutyricum* and engineer the strain for high-level butanol production. Metabolic Engineering 2018, 47, 49-59. cited by applicant

Lehmann, D., Hönicke, D., Ehrenreich, A., Schmidt, M., et al., Modifying the product pattern of *Clostridium acetobutylicum*: physiological effects of disrupting the acetate and acetone formation pathways. Applied Microbiology and Biotechnology 2012, 94, 743-754. cited by applicant

Yu, M. R., Zhang, Y. L., Tang, I. C., Yang, S. T., Metabolic engineering of *Clostridium tyrobutyricum* for n-butanol production. Metabolic Engineering 2011, 13, 373-382. cited by applicant

Pyne et al., Harnessing heterologous and endogenous CRISPR-Cas machineries for efficient markerless genome editing in *Clostridium*, Scientific Reports, May 2016, 1-15. cited by applicant

Primary Examiner: Monshipouri; Maryam

Attorney, Agent or Firm: Barnes & Thornburg LLP

Background/Summary

CROSS REFERENCE TO RELATED APPLICATIONS (1) This application is a divisional application of U.S. Ser. No. 16/811,733, filed Mar. 6, 2020, which claims priority to U.S. Provisional Patent Application No. 62/815,198 filed Mar. 7, 2019. The disclosures of which are hereby expressly incorporated by reference in its entirety.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

(1) Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: a 40 kilobytes ACII (Text) file named "314658ST25.txt" created on Feb. 20, 2020.

BACKGROUND

(2) n-butanol (butanol hereafter) is used as a solvent, paint thinner, perfume, and more recently as a source of renewable fuel. Hence, methods to enhance butanol production are a major focus. However, traditional chemical synthesis methods employed for butanol production are costly and laborious. Furthermore, these methods generate unwanted byproducts and environmental pollutants. Alternative approaches continue to be investigated for their ability to overcome these limitations while also significantly increasing the yield of desired products, particularly butanol. These alternatives include the use of microbial host strains that can be exploited for their natural ability to produce butanol.

(3) Clostridia are a type of bacteria that have long been studied for biobutanol production through their acetone-butanol-ethanol (ABE) fermentation pathway. Although large scale production has already been established using clostridia, there are several obstacles that prevent it from being economically feasible, including high costs and low yields associated with batch fermentation of currently available Clostridia strains.

(4) Recent efforts have focused on modifying the ABE fermentation pathway of clostridia in order to reduce unwanted byproducts while increasing overall yield of butanol. One method used to achieve these modifications involves the use of CRISPR-Cas9 systems which have been widely used as a genome editing tool for numerous types of bacteria. However, conventional CRISPR methods are limited by severe toxicity to the host cells and thus in many cases are difficult to implement. Hence, alternative strategies are needed to improve butanol production while also overcoming existing limitations.

(5) Clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-associated (Cas) system is an RNA guided immune system in bacteria and archaea that can provide defense against foreign invaders, such as phages and plasmids. Most currently identified CRISPR-Cas systems share similar features, consisting of identical direct repeats separated by variable spacers, along with a suite of associated cas genes. CRISPR-Cas systems can be classified into two classes and six types based on the signature Cas proteins and the architecture of CRISPR-cas loci. A complex of multiple Cas proteins are involved in degrading the invading genetic elements in Types I, III and IV, which all belong to the Class 1 system; while Types II, V and VI in the Class 2 system can carry out the same operation by using a single large Cas protein. Among the various

CRISPR-Cas systems, Type I, II, and III are the most widespread in both archaea and bacteria, and distinguished by the presence of the unique signature protein: Cas3, Cas9, and Cas10, respectively. Among them, Type I systems exhibit the most diversity, and are further divided into six subtypes: I-A to I-F.

(6) Three functional stages, termed adaptation, expression, and interference, are generally included in the development of the immunity of CRISPR-Cas systems for the defense of the potential foreign invaders. During the adaptation phase, spacer sequences derived from the invading genetic elements are identified and integrated into the host genome right between the leader sequence and the first spacer, generating the new spacers of the CRISPR array. A promoter located within the CRISPR leader sequence then drives the transcription of CRISPR array (including the new spacers) to form a long precursor CRISPR RNA (crRNA) followed by the cleavage of the precursor crRNAs to make mature crRNAs. Once the invasion happens again to the host cells, a ribonucleoprotein complex (crRNP) will be formed by the mature crRNAs and specific Cas proteins to recognize the same or similar foreign genetic elements through sequence matching between the spacer on the crRNA and the protospacer on the foreign invaders, and degrade the invading DNA or RNA via interference. During the interference in Type I and Type II systems, the targeting efficiency is greatly improved if the protospacer is flanked by a short conserved sequence defined as protospacer-adjacent motif (PAM). The PAM sequence is usually 2-5 nucleotides long and located at the 5'- or 3'-end of the protospacer. The presence of PAM sequence in the target DNA rather than in the CRISPR array of the host genome is used to discriminate 'self' and 'non-self'.

(7) Although the Class 2 system is less abundant in nature, their acting machineries are much simpler and more programmable. In the past few years, the *Streptococcus pyogenes* CRISPR-Cas9 (spCRISPR-Cas9) system has been engineered to be a high efficient genome editing tool that has been implemented in a broad range of organisms, such as bacteria, yeast, plants, mammal cells, and human cells. Besides single gene knock-in or knock-out, successes have also been reported for multiplex genome editing and transcriptional regulation, including repression and activation. Recently, another Class 2 CRISPR effector, Cpf1, was characterized and repurposed for genome editing. Compared to the CRISPR-Cas9 system, the CRISPR-Cpf1 system exhibited higher targeting efficiency and capability under particular circumstances.

(8) CRISPR-Cas9/Cpf1 systems have proven to be powerful genome engineering tools with which versatile genome editing purposes can be achieved. However, as a heterologous protein, in many cases, either Cas9 or Cpf1 is hard to introduce into bacteria and archaea due to their intrinsic toxicity, leading to low transformation efficiency and thus difficulty for genome editing.

(9) It has been reported that, based on genome analysis, approximately 47% of sequenced bacteria and 87% of sequenced archaea harbor CRISPR-cas loci. Therefore, endogenous CRISPR-Cas systems have the potential to be repurposed for genome editing and transcriptional regulation. Through the deletion of cas3 gene which is responsible for degrading the target DNA, the endogenous Type I-E CRISPR-Cas system in *Escherichia coli* was harnessed as a programmable gene expression regulator. Pyne et al. engineered the Type I-B CRISPR-Cas system in *Clostridium pasteurianum* to be an efficient genome editing tool, and successfully deleted the cpaAIR gene (Pyne et al., 2016, Sci. Rep. 6, 25666).

(10) In recent years, the genus *Clostridium* has drawn tremendous attentions as it contains various strains with great potentials for the production of commodity chemicals and fuels, such as butanol. Butanol can be naturally produced in solventogenic clostridia through the Acetone-Butanol-Ethanol (ABE) fermentation. Although tremendous efforts have been invested on the metabolic engineering of solventogenic clostridial strains for enhanced biobutanol production, only very limited success has been achieved. This is because, on one hand, there are several intrinsic byproducts in ABE fermentation including fatty acids, acetone and ethanol that are hard to eliminate; on the other, the ABE fermentation for butanol production goes through a biphasic process and is subjected to complicated metabolic regulation.

(11) Yu et al. engineered *C. tyrobutyricum* ATCC 25755 (a hyper-butyrate producer) for butanol production by inactivating the native acetate kinase (ack) gene or the phosphate ++ (ptb) gene and introducing the aldehyde/alcohol dehydrogenase (adhE2) from *C. acetobutylicum*, to generate a strain that produces a butanol titer of 10.0 g/L (Yu et al., 2011, Metab. Eng. 13, 373-82). Recently, the butyrate-producing metabolism of *C. tyrobutyricum* was further elucidated through whole-genome sequencing and proteomic analysis. Interestingly, contradictory with the results by Yu et al. (Yu et al., 2011), it was demonstrated that the ptb gene actually does not exist in *C. tyrobutyricum* and the ack gene can't be deleted because the deletion would lead to no end product and inefficient ATP generation. Additionally, it was revealed that the butyrate production in *C. tyrobutyricum* is in fact dependent on the butyrate:acetate CoA transferase gene (cat1), which is very different from the ptb-butyrate kinase (buk) pathway for butyrate production in solventogenic clostridial strains. However, the disruption of cat1 using mobile group II intron was unsuccessful, because the inactivation of cat1 would likely lead to the inability of the strain to carry out NADH oxidization.

(12) Accordingly a need still exists for a bacterial strain that has high levels of butanol production with decreased levels of undesirable by products such as fatty acids and acetone. Applicants provide herein a modified endogenous *C. tyrobutyricum* CRISPR-Cas system under the control of an inducible promoter for modifying the genome of clostridia. This system was used to generate a modified *C. tyrobutyricum* that produces at least 20 g/L of butanol after 72 hours in a standard batch fermentation process.

SUMMARY

(13) As disclosed herein, an efficient genome editing tool for *C. tyrobutyricum*, is provided, based on the endogenous Type I-B CRISPR-Cas system. The PAM sequences for DNA targeting purposes were identified through in silico CRISPR array analysis and in vivo plasmid interference assays. By using a lactose inducible promoter to drive the transcription of the CRISPR array, multiplex genome engineering purposes have been achieved, with an editing efficiency as high as 100%.

(14) In accordance with one embodiment a method of editing a bacterial genome is provided wherein the method utilizes an endogenous CRISPR-Cas system. One component of the system is a synthetic CRISPR array that is optionally expressed under the control of an inducible promoter. The CRISPR array encodes a spacer RNA that targets a protospacer sequence contained within the bacterial genome. The encoded array in conjunction with the native *Clostridium* Cas protein forms a complex that will cleave the targeted DNA. In one embodiment the method comprises introducing an exogenous nucleic acid into the bacterial cell wherein the exogenous nucleic acid comprises a sequence that encodes a synthetic CRISPR array that is operably linked to an inducible promoter, and optionally the exogenous nucleic acid further comprises nucleic acid sequences that are homologous to sequences flanking the target protospacer sequence to facilitate the modification of the target genome loci through homologous recombination.

(15) In accordance with one embodiment the endogenous CRISPR-Cas system of *C. tyrobutyricum*, was used to successfully engineer *C. tyrobutyricum* for enhanced butanol production. By introducing an adhE2 gene and inactivating the native cat1 gene, the obtained mutant produced a record high of 26.2 g/L butanol in a batch fermentation. This mutant bacterial strain of *Clostridium tyrobutyricum* JZ100 was deposited in accordance with the provisions of the Budapest Treaty on Nov. 5, 2017, with the Agriculture Research Culture Collection (NRRL), an International Depository Authority located at 1815 N. University Street, Peoria, IL 61604 and assigned accession number B-67519. This deposited strain can be used as a robust workhorse for efficient biobutanol production from low-value carbon sources, and can be further engineered for enhanced butanol and other valuable biochemical production.

(16) In accordance with one embodiment a vector for introducing modifications into a target genomic site of bacteria, optionally a *Clostridium* strain, via an endogenous CRISPR-Cas complex is provided. In one embodiment the vector comprises a synthetic CRISPR array, an inducible promoter operably linked to the synthetic CRISPR array, and a first homology arm polylinker site.

In one embodiment the vector further comprises a native *Clostridium tyrobutyricum* Cas encoding sequence. In one embodiment the synthetic CRISPR array comprises a first spacer polylinker site, a first and second direct repeat sequence, and a CRISPR terminator sequence. In one embodiment the first and second direct repeat sequence have greater than 95% sequence identity to one another, or optionally, have 100% sequence identity to one another, and the first spacer polylinker site is located between the first and second direct repeat sequence.

(17) In one embodiment a vector for introducing modifications into a target genomic site of a *Clostridium* strain is provided wherein the vector comprises a synthetic CRISPR array, a lactose inducible promoter operably linked to the synthetic Type I-B CRISPR array, a first homology arm polylinker site, and optionally a CRISPR terminator sequence. In one embodiment the synthetic CRISPR array comprises a first spacer polylinker site, and a first and second direct repeat sequences, wherein the first and second direct repeat sequences each comprise a sequence of SEQ ID NO: 2; and the first spacer polylinker site located between the first and second direct repeat sequences. In a further embodiment the CRISPR terminator sequence comprises the sequence of SEQ ID NO 3.

(18) In accordance with one embodiment a vector for multiplex modification of a bacterial genome, optionally a *Clostridium* strain, via a CRISPR-Cas complex is provided. In one embodiment the vector comprises a synthetic CRISPR array, an inducible promoter operably linked to the synthetic CRISPR array, a first homology arm polylinker site and a second homology arm polylinker site. In one embodiment the synthetic CRISPR array comprises a first spacer polylinker site a second spacer polylinker site, and a first, second and third direct repeat sequences, wherein the first, second and third direct repeat sequences each have greater than 95% sequence identity, or optionally at least 99% sequence identity to the sequence of SEQ ID NO: 2, and the first spacer polylinker site is located between the first and second direct repeat sequences and the second spacer polylinker site located between the second and third direct repeat sequences, and a CRISPR terminator sequence located after the third direct repeat sequence.

(19) In accordance with one embodiment a recombinant *Clostridium* strain is provided that has been modified for enhanced butanol production. In one embodiment, the *Clostridium* strain produces at least 20 g/L of butanol after 72 hours of culture in a standard batch culture procedure using glucose as the carbon source. In one embodiment the modified *Clostridium* strain comprises an exogenous gene encoding for aldehyde dehydrogenase activity, optionally wherein the exogenous gene has been inserted into the native cat1 gene and prevents expression of a functional cat1 gene product. In one embodiment the exogenous aldehyde dehydrogenase gene is a dual aldehyde/alcohol dehydrogenase gene including for example a *C. acetobutylicum* gene selected from the group consisting of adhE1 and adhE2. In one embodiment the recombinant *Clostridium* strain is selected from the group consisting of *Clostridium butyricum*, *Clostridium thermobutyricum*, *Clostridium cellulovorans*, *Clostridium carboxidivorans*, *Clostridium tyrobutyricum*, *Clostridium polysaccharolyticum*, *Clostridium populeti*, and *Clostridium kluyveri*. In one embodiment the *Clostridium* strain is *Clostridium tyrobutyricum*.

(20) In one embodiment a method of biosynthetically producing butanol is provided, wherein a modified *Clostridium* strain is cultured under conditions suitable for growth of the strain, and the butanol produce by the cell is recovered. In one embodiment the modified *Clostridium* strain comprises a modification to the native cat1 gene (wherein the modification inhibits or prevents expression of a functional cat1 gene product); and an exogenous aldehyde dehydrogenase gene, optionally wherein the aldehyde dehydrogenase gene is inserted in to the genome of the *Clostridium* strain. Optionally the exogenous aldehyde dehydrogenase gene encodes a polypeptide having alcohol dehydrogenase and aldehyde dehydrogenase activity. In one embodiment the exogenous aldehyde dehydrogenase gene is selected from the group consisting of adhE1 and adhE2, optionally wherein the adhE1 gene encodes a polypeptide having at least 95% sequence identity to the polypeptide of SEQ ID NO: 133 and the adhE2 gene encodes a polypeptide having

at least 95% sequence identity to the polypeptide of SEQ ID NO: 134. In accordance with one embodiment the *Clostridium* strain comprises a cat1 gene modified by the insertion of an adhE1 or adhE2 gene into the cat1 gene, rendering the cat1 gene incapable of expressing a functional gene product. In one embodiment the culturing step comprises culturing the modified *Clostridium* strain at a temperature less than 37° C., optionally at a temperature selected from the range of about 20° C. to about 30° C.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIGS. 1A & 1B Characterization of the Type I-B CRISPR-Cas system in *C. tyrobutyricum*. FIG. 1A is a schematic diagram showing the structure of the central Type I-B CRISPR-Cas locus in the genome of *C. tyrobutyricum*. The central CRISPR-Cas locus possesses a representative Type I-B cas operon including cas6-cas8b-cas7-cas5-cas3-cas4-cas1-cas2 (labeled “cas68b753412”) followed by a leader sequence and the Array2 containing 8 distinct spacers (diamonds) separated by 30-nt direct repeats (rectangles) and a CRISPR terminator sequence (open circle). The transcription of Array2 is driven by a promoter within the leader sequence. FIG. 1B provides sequence assignments providing an identification of putative protospacer matches via in silico analysis of *C. tyrobutyricum* CRISPR spacers. Only five nt of the 5'- and 3'-end adjacent sequences are provided. Array1-17 (SEQ ID NO: 19); *C. thermocellum* ATCC 27405 (SEQ ID NO: 20) and *Geobacillus* sp. Y4.1MC1 (SEQ ID NO: 21).

(2) FIGS. 2A & 2B Identification of protospacer adjacent motif (PAM) sequences of the Type I-B CRISPR-Cas system in *C. tyrobutyricum*. FIG. 1A provides a map of plasmids used in systematic mutagenesis assays, including the protospacer (SEQ ID NO: 21) with a 5' PAN sequence. Mutation positions were indicated on the PAM sequence. Array2-1 (Table 1) was used as the protospacer. FIG. 2B presents data in a bar graph testing several variant PAM sequences used in the assay and their corresponding transformation efficiencies. The plasmid pMTL82151 (PAM, —; Mutation position, —) was used as the control. Data are based on at least two independent replicates.

(3) FIGS. 3A-3D: Markerless genome editing in *C. tyrobutyricum* using the endogenous Type I-B CRISPR-Cas system. FIG. 3A provides a schematic drawing that illustrates the steps involved in deleting the spo0A gene via a lactose inducible CRISPR-Cas system. The lactose inducible promoter was used to drive the transcription of synthetic CRISPR array, wherein the array comprises a spacer (diamonds) separated by 30-nt direct repeats (rectangles). ~1 kb upstream and downstream homology arms (flanking the native spo0A gene) were used for the deletion of spo0A gene. Two screening steps are involved in the process. In the first step, the plasmid was transformed into *C. tyrobutyricum* under the selection of thiamphenicol (Tm). In the second step, lactose was applied to induce the transcription of synthetic CRISPR array and eliminate the wild type background cells, thus selecting for the desirable mutant. Pairs of half arrows and the numbers in the figure indicate the cPCR target regions and the PCR amplicon sizes, respectively. FIG. 3B is a table presenting the various plasmids carrying the CRISPR-Cas9/nCas9/AsCpf1 and Type I-B CRISPR-Cas systems that were tested for the deletion of spo0A. Promoters and the length of spacers were optimized for the CRISPR-Cas system in order to improve the transformation efficiency and editing efficiency. The inducible promoters tested include the lactose inducible promoter (Plac) and the arabinose inducible promoter (Para). FIG. 3C provides data in a bar graph format showing the transformation efficiency of different plasmids. Data are based on at least two independent replicates. FIG. 3D provides data in a bar graph format demonstrating the genome editing efficiency of different plasmids that can be transformed into *C. tyrobutyricum*. Fifteen colonies of each transformant were picked and screened for mutation. The editing efficiency were calculated as the ratio of the number of spo0A mutants to the total of fifteen colonies.

(4) FIGS. 4A-4C: Multiplex gene editing in *C. tyrobutyricum* using the inducible endogenous Type I-B CRISPR-Cas system. FIG. 4A provides a schematic drawing illustrating the use of the lactose inducible CRISPR-Cas system to conduct a double deletion of both the *spo0A* and *pyrF* genes. The deletion vector comprises a CRISPR array under the control of a lactose promoter and including spacers (diamonds) targeting the *spo0A* and *pyrF* genes, respectively, where each spacer is flanked by a 30 nucleotide direct repeat (rectangles) and a nucleic acid sequence of ~1.2 kb upstream and downstream of both *spo0A* and *pyrF*, respectively (~300 bp each) used to create homology arms to induce homologous recombination after cleavage by the CRISPR-Cas system. The screening procedure of double deletion was similar with that for single deletion, except that a series of subculturing was required before plating the culture on the TGYLTU plates. Pairs of half arrows and the numbers in the figure indicate the cPCR target regions and the PCR amplicon sizes, respectively. Detection of gene deletion events was carried out at the 8th (FIG. 4B) and 15th (FIG. 4C) generations during the subculturing. Single deletion vectors pJZ77-Plac-30*spo0A* and pJZ77-Plac-30*pyrF* were used as controls. 47 colonies of each transformant were picked and screened for mutations. The white rectangles, grey rectangles, and black rectangles represent wild type strain, single deletion mutant of *spo0A* or *pyrF*, and double deletion mutant, respectively.

(5) FIG. 5 provides a schematic diagram of the metabolic pathway of Δ *cat1::adhE1* and Δ *cat1::adhE2* mutants. The major products of the two mutants are ethanol and butanol and the biosynthesis pathways which are absent in the wild type strain are shown in grey boxes. The butyrate biosynthesis pathway which is disrupted from the wild type strain is shown with dotted lines. Key genes in the pathway: *pfor*, pyruvate::ferredoxin oxidoreductase; *hyda*, hydrogenase; *fnor*, ferredoxin NAD_{sup}.+ oxidoreductase; *pta*, phosphotransacetylase; *ack*, acetate kinase; *thl*, thiolase; *hbd*, beta-hydroxybutyryl-CoA dehydrogenase; *crt*, crotonase; *bcd*, butyryl-CoA dehydrogenase; *cat1*, butyrate:acetate coenzyme A transferase; *adhE1/adhE2*, aldehyde-alcohol dehydrogenase.

(6) FIGS. 6A & 6B show alignments of the *C. tyrobutyricum* and *C. pasteurianum* leader sequences (FIG. 6A; SEQ ID NO: 23 and 24, respectively) and the *C. tyrobutyricum* Array1, Array2 and *C. pasteurianum* direct repeat sequences (FIG. 6B; SEQ ID NO: 18, 2 and 25, respectively) of the CRISPR array.

(7) FIGS. 7A-7E: Fermentation profiles of *C. tyrobutyricum* WT(pJZ98-P*cat1-adhE1*) and mutant Δ *cat1::adhE1* strains. Graphs are provided demonstrating the amount of glucose (.box-tangle-solidup.), acetate (.circle-solid.), ethanol (°), butyrate (Δ) and butanol (.square-solid.) detected over time when *C. tyrobutyricum* strains are cultured under different temperatures, using glucose as a carbon source. FIG. 7A provides the results from culturing WT(pJZ98-P*cat1-adhE1*) at 37° C.; FIG. 7B provides the results from culturing mutant Δ *cat1::adhE1* at 37° C.; FIG. 7C provides the results from culturing mutant Δ *cat1::adhE1* at 30° C.; FIG. 7D provides the results from culturing mutant Δ *cat1::adhE1* at 25° C.; and FIG. 7E provides the results from culturing mutant Δ *cat1::adhE1* at 20° C. Values are based on at least two independent replicates.

(8) FIG. 8A-8E: Fermentation profiles of *C. tyrobutyricum* WT(pJZ98-P*cat1-adhE1*) and mutant Δ *cat1::adhE2* strains. Graphs are provided demonstrating the amount of glucose (.box-tangle-solidup.), acetate (.circle-solid.), ethanol (°), butyrate (Δ) and butanol (.square-solid.) detected over time when *C. tyrobutyricum* strains are cultured under different temperatures, using glucose as a carbon source. FIG. 8A provides the results from culturing WT(pJZ98-P*cat1-adhE2*) at 37° C.; FIG. 8B provides the results from culturing mutant Δ *cat1::adhE2* at 37° C.; FIG. 8C provides the results from culturing mutant Δ *cat1::adhE2* at 30° C.; FIG. 8D provides the results from culturing mutant Δ *cat1::adhE2* at 25° C.; and FIG. 8E provides the results from culturing mutant Δ *cat1::adhE2* at 20° C. Values are based on at least two independent replicates.

DETAILED DESCRIPTION

Definitions

(9) In describing and claiming the invention, the following terminology will be used in accordance

with the definitions set forth below.

(10) The term “about” as used herein means greater or lesser than the value or range of values stated by 10 percent, but is not intended to designate any value or range of values to only this broader definition. Each value or range of values preceded by the term “about” is also intended to encompass the embodiment of the stated absolute value or range of values.

(11) As used herein an “amino acid modification” defines a substitution, addition or deletion of one or more amino acids, and includes substitution with or addition of any of the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids.

(12) The term “substantially purified polypeptide/nucleic acid” refers to a polypeptide/nucleic acid that may be substantially or essentially free of components that normally accompany or interact with the polypeptide/nucleic acid as found in its naturally occurring environment.

(13) A “recombinant host cell” or “host cell” refers to a cell that includes an exogenous polynucleotide, regardless of the method used for insertion. The exogenous polynucleotide may be maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

(14) As to amino acid sequences, one of ordinary skill in the art will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the deletion of an amino acid, addition of an amino acid, or an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are known to those of ordinary skill in the art. The following eight groups each contain amino acids that are conservative substitutions for one another:

(15) TABLE-US-00001 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M)

(16) The term “linkage” or “linker” is used herein to refer to groups or bonds that normally are formed as the result of a chemical reaction and typically are covalent linkages.

(17) An “operable linkage” is a linkage in which a promoter sequence or promoter control element is connected to a polynucleotide sequence (or sequences) in such a way as to place transcription of the polynucleotide sequence under the influence or control of the promoter or promoter control element. Two DNA sequences (such as a polynucleotide to be transcribed and a promoter sequence linked to the 5' end of the polynucleotide to be transcribed) are said to be operably linked if induction of promoter function results in the transcription of an RNA.

(18) The term “isolated” requires that the referenced material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

(19) As used herein, the term “peptide” encompasses a sequence of 3 or more amino acids and typically less than 50 amino acids, wherein the amino acids are naturally occurring or non-naturally occurring amino acids. Non-naturally occurring amino acids refer to amino acids that do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide structures described herein.

(20) As used herein, the terms “polypeptide” and “protein” are terms that are used interchangeably to refer to a polymer of amino acids, without regard to the length of the polymer. Typically, polypeptides and proteins have a polymer length that is greater than that of “peptides.”

(21) As used herein a general reference to a polypeptide is intended to encompass polypeptides that have modified amino and carboxy termini. For example, an amino acid chain comprising an amide group in place of the terminal carboxylic acid is intended to be encompassed by an amino acid

sequence designating the standard amino acids.

(22) As used herein an amino acid “substitution” refers to the replacement of one amino acid residue by a different amino acid residue.

(23) As used herein, the term “CRISPR-Cas system” defines a complex comprising a Cas protein and a spacer RNA.

(24) The terms “target sequence,” “target DNA,” and “target site” are used interchangeably to refer to the specific sequence in chromosomal DNA to which the engineered CRISPR-Cas system is targeted, and the site at which the engineered CRISPR-Cas system modifies the DNA.

(25) The terms “upstream” when used in the context of a nucleic acid sequence, identifies a nucleic acid sequence that is located on the 5' side of a reference nucleic acid sequence. For example a promoter is located upstream of a nucleic acid coding sequence.

(26) The terms “downstream” when used in the context of a nucleic acid sequence identify nucleic acid sequence that are located on the 3' side of a reference nucleic acid sequence. For example a transcriptional terminator sequence is located downstream of a nucleic acid coding sequence.

(27) The term “direct repeat sequence” defines an RNA strand that participates in recruiting a CRISPR endonucleases to the target site.

(28) As used herein the term “guide sequence” or “spacer” defines a DNA sequence that transcribes an RNA strand that hybridizes with the target DNA.

(29) The term “protospacer” refers to the DNA sequence targeted by a spacer sequence. The protospacer typically comprises the spacer sequence covalently linked to a protospacer adjacent motif (PAM). PAM is a 2-6-base pair DNA sequence immediately preceding or following the DNA sequence targeted by the Cas nuclease in the CRISPR-Cas system. In some embodiments, the protospacer sequence hybridizes with the spacer sequence of the CRISPR-Cas system.

(30) The term “endogenous” as used herein, refers to a natural state. For example a molecule (such as a direct repeat sequence) endogenous to a cell is a molecule present in the cell as found in nature. A “native” compound is an endogenous compound that has not been modified from its natural state.

(31) As used herein, the term “exogenous” refers to a molecule not present in the composition found in nature. A nucleic acid that is exogenous to a cell, or a cell's genome, is a nucleic acid that comprises a sequence that is not native to the cell/cell's genome.

Embodiments

(32) As disclosed herein, an efficient genome editing tool for *C. tyrobutyricum*, is provided, based on the endogenous Type I-B CRISPR-Cas system. Advantageously, this novel genome editing tool has been used to modify the genome of *Clostridium* strain to produce a novel strain having improved production of butanol.

(33) In accordance with one embodiment a recombinant microorganism is provided that produces butanol while the microorganism is cultured under conditions favorable for growth. In particular, in one embodiment a microorganism has been modified for increased expression of aldehyde dehydrogenase activity by the addition of an exogenous gene that encodes for aldehyde dehydrogenase activity, optionally wherein the ability of the cat1 gene to produce a functional protein has been decreased or eliminated. In one embodiment the recombinant microorganism has been modified by the integration of an exogenous gene encoding for aldehyde dehydrogenase activity, optionally wherein the exogenous gene also encodes for alcohol dehydrogenase activity. In one embodiment the dehydrogenase activity is an alcohol dehydrogenase activity. In one embodiment the exogenous gene encodes for both aldehyde dehydrogenase activity and alcohol dehydrogenase activity. In one embodiment the exogenous gene is an aldehyde/alcohol dehydrogenase gene having at least about 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 133 or SEQ ID NO: 134. In one embodiment the exogenous gene is the adhE1 or adhE2 gene from *C. acetobutylicum*.

(34) In one embodiment the modified microorganism is a *Clostridium* strain, including for example

a *Clostridium* strain selected from the group consisting of *Clostridium butyricum*, *Clostridium thermobutyricum*, *Clostridium cellulovorans*, *Clostridium carboxidivorans*, *Clostridium tyrobutyricum*, *Clostridium polysaccharolyticum*, *Clostridium populeti*, and *Clostridium kluyveri*. In one embodiment the *Clostridium* strain is *Clostridium tyrobutyricum*.

(35) In one embodiment a recombinant *Clostridium* strain modified for enhanced butanol production is provided wherein the *Clostridium* strain comprises an exogenous aldehyde dehydrogenase gene inserted in to the genome of the *Clostridium* strain and a modification to the native cat1 gene, wherein the modification inhibits or prevents expression of a functional cat1 gene product. In one embodiment the exogenous aldehyde dehydrogenase gene encodes for both alcohol dehydrogenase and aldehyde dehydrogenase activity, including for example a *C. acetobutylicum* gene selected from the group consisting of adhE1 and adhE2. In one embodiment the dehydrogenase gene is an adhE1 gene that encodes a protein having at least 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 133. In one embodiment the dehydrogenase gene is an adhE2 gene that encodes a protein having at least 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO: 134. In accordance with one embodiment a modified *Clostridium* is provided wherein the cat1 gene is modified by the insertion of an adhE1 or adhE2 gene into the cat1 gene rendering the cat1 gene incapable of expressing a functional gene product.

(36) In accordance with one embodiment a modified strain of *Clostridium* is provided wherein butanol is produced by the organism at a level of at least 15 g/L, when the cells are cultured at a temperature selected from about 20° C. to about 30° C. in the presence of a carbon source such as glucose. In accordance with one embodiment a modified strain of *Clostridium* is provided wherein butanol is produced by the organism at a level of at least 20 g/L, when the cells are cultured at a temperature selected from about 20° C. to about 30° C. In accordance with one embodiment a modified strain of *Clostridium* is provided wherein butanol is produced by the organism at a level of at least 15 g/L wherein the levels of acetate and ethanol are less than 10 g/L, when the cells are cultured at a temperature selected from about 20° C. to about 30° C.

(37) In accordance with one embodiment a recombinant *Clostridium* strain is provided, wherein the strain when cultured at a temperature of less than 30° C. using glucose as a carbon source, produces at least 20 g/L of butanol, and less than 15 g/L of acetate, after 72 hours of culture. In accordance with one embodiment a recombinant *Clostridium* strain is provided, wherein the strain when cultured at a temperature of selected from a range of about 20° C. to about 30° C. using glucose as a carbon source, produces at least 25 g/L of butanol, and less than 15 g/L of acetate, after 120 hours of culture. In one embodiment the *Clostridium* strain is *Clostridium tyrobutyricum*.

(38) In one embodiment a *Clostridium* strain modified for enhanced butanol production is provided wherein the strain comprises an exogenous gene encoding for aldehyde dehydrogenase activity, and a modified native *Clostridium* cat1 gene, wherein the modification prevents expression of a functional cat1 gene product, further wherein the modified strain, when cultured at a temperature of less than 30° C. using glucose as a carbon source, produces at least 20 g/L of butanol after 72 hours of culture. In one embodiment the exogenous gene is inserted into the cat1 gene rendering the cat1 gene incapable of expressing a functional gene product. In one embodiment the exogenous gene is an adhE gene having at least 95% sequence identity to SEQ ID NO: 133 or SEQ ID NO: 134. In one embodiment the exogenous gene is an adhE1 or adhE2 gene.

(39) In one embodiment a *Clostridium* strain modified for enhanced butanol production is provided wherein the strain comprises a modification to the native cat1 gene, wherein the modification preventing expression of a functional cat1 gene product, and an exogenous sequence encoding i) an aldehyde dehydrogenase; ii) a bifunctional aldehyde/alcohol dehydrogenase; or iii) an aldehyde dehydrogenase and an alcohol dehydrogenase. In one embodiment the *Clostridium* strain is a recombinant organism wherein the cat1 gene is modified by the insertion of the exogenous sequence into the cat1 gene rendering the cat1 gene incapable of expressing a functional gene product. More particularly, in one embodiment the recombinant *Clostridium* strain the inserted

exogenous sequence comprises an bifunctional alcohol/aldehyde dehydrogenase gene selected from the group consisting of adhE1 and adhE2, wherein the strain, when cultured at a temperature of less than 30° C. using glucose as a carbon source, produces at least 20 g/L of butanol after 72 hours of culture.

(40) In accordance with one embodiment a recombinant *Clostridium* strain modified for enhanced butanol production is provided wherein the *Clostridium* strain comprises an exogenous gene encoding for aldehyde dehydrogenase activity inserted into the genome of the strain, and a modified native *Clostridium* cat1 gene, wherein the modification to the native *Clostridium* cat1 gene prevents expression of a functional cat1 gene product. In one embodiment, the recombinant *Clostridium* strain, when cultured at a temperature of less than 30° C. using glucose as a carbon source, produces at least 20 g/L of butanol and less than 15 g/L of acetate after 72 hours of culture. In one embodiment the exogenous gene encoding for aldehyde dehydrogenase activity is an adhE1 or adhE2 gene that is inserted into the *Clostridium* native cat1 gene rendering the cat1 gene incapable of expressing a functional gene product. In one embodiment a modified *Clostridium tyrobutyricum* strain (*Clostridium tyrobutyricum* JZ100) is provided that has enhanced production of butanol relative to the native strain. A representative sample of this modified strain was deposited in accordance with the provisions of the Budapest Treaty on Nov. 5, 2017, with the Agriculture Research Culture Collection (NRRL), an International Depository Authority located at 1815 N. University Street, Peoria, IL 61604, and assigned accession number B-67519.

(41) In accordance with one embodiment the novel modified microorganisms described herein are used in methods of producing butanol and other biofuels. In certain of these embodiments, the methods include culturing one or more different recombinant microorganisms in a culture medium, and accumulating butanol in the culture medium. In one embodiment a method of producing butanol is provided wherein a recombinant *Clostridium* strain modified for enhanced butanol production is cultured under conditions suitable for growth of the strain, and the butanol produced by the cells are recovered. In one embodiment the cultured *Clostridium* strain is a strain that has been modified to inactivate the native cat1 gene, and further modified to have enhanced aldehyde dehydrogenase and alcohol dehydrogenase activity. In one embodiment the enhanced aldehyde dehydrogenase activity is provided by introducing an exogenous aldehyde dehydrogenase gene into the *Clostridium* strain, optionally inserting an exogenous aldehyde dehydrogenase into genome of the cell and in one embodiment inserting the aldehyde dehydrogenase gene into the native cat1 gene and thus inactivating the cat1 gene. In one embodiment the exogenous aldehyde dehydrogenase gene is a bifunctional aldehyde/alcohol dehydrogenase including for example adhE1 or adhE2.

(42) In one embodiment the method of producing butanol comprises culturing a novel *Clostridium* strain as disclosed herein at a temperature less than 37° C. Optionally the *Clostridium* strain is cultured at a temperature selected from the range of about 20° C. to about 35° C., or about 20° C. to about 30° C., or about 25° C. to about 30° C., or about 20° C. to about 25° C., or at about 30° C., or at about 25° C. or at about 20° C.

(43) In accordance with one embodiment a method of editing a bacterial genome is provided that is based on a modified endogenous CRISPR array. One embodiment of the present disclosure is directed to an enhanced butanol producing *Clostridium* strain produced by the novel CRISPR-CAS system disclosed herein and the use of such novel strains to produce butanol.

(44) In one embodiment the novel CRISPR-CAS system comprises an endogenous CRISPR array under the control of an inducible promoter that drives the expression of a spacer RNA that targets a protospacer sequence contained within a bacterial genome, resulting in a double strand break in the targeted DNA. In one embodiment a method of modifying a *Clostridium* strain comprises introducing an exogenous nucleic acid (i.e., a vector) into the bacterial cell wherein the exogenous nucleic acid comprises a sequence that encodes a synthetic CRISPR array under the control of an inducible promoter. In one embodiment the synthetic CRISPR array comprises a first and second

direct repeat, a spacer polylinker site, wherein the spacer polylinker site is located between the first and second direct repeat, and a CRISPR terminator sequence located after the second direct repeat. The spacer polylinker site provides a plurality of restriction enzyme target sequences that allow for the easy insertion of a spacer sequence of choice. Advantageously, this vector allows one to substitute sequences to direct the CRISPR-CAS system to modify a target protospacer sequence of choice present in the bacterial genome. The modification of the target sequence can be enhanced by including sequences that are homologous to the upstream and/or downstream regions of the target protospacer. Accordingly, in one embodiment the exogenously introduced nucleic acid (vector) comprises a homology arm polylinker site, wherein the homology arm polylinker site comprises a plurality of restriction enzyme target sequences, that differ from those of the spacer polylinker site, and allow for the easy insertion of sequences homologous to the upstream and/or downstream regions of the target protospacer.

(45) In one embodiment the first and second direct repeat are based on the endogenous Type I-B CRISPR-Cas system of *C. tyrobutyricum*. The direct repeats will typically be identical in sequence relative to one another but in one embodiment the direct repeat sequences can vary by one or two nucleotide differences or the two direct repeats can have greater than 95% or 99% sequence identity to one another and are orientated relative to each other as direct repeated sequences on either side of a spacer polylinker/spacer sequence. In one embodiment the direct repeats comprise a sequence that has at least 80%, 85%, 90% 95% or 99% sequence identity to SEQ ID NO: 2. In one embodiment the two direct repeat sequences independently comprise a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 2. In one embodiment the two direct repeat sequences each comprise the sequence of SEQ ID NO: 2.

(46) In one embodiment the exogenously nucleic acid sequence further comprises sequence encoding for a *Clostridium tyrobutyricum* Cas protein. A vector that further comprises the *Clostridium tyrobutyricum* Cas protein can beneficially be used to induce modifications into *Clostridium* strains other than *Clostridium tyrobutyricum* through the use of the CRISPR-Cas system disclosed herein.

(47) In accordance with one embodiment a vector for introducing modifications into a target genomic site of bacteria via a CRISPR-Cas complex is provided, wherein the target genomic site is a contiguous nucleic acid sequence comprising a first protospacer sequence, a first upstream sequence and a first downstream sequence. More particularly, in one embodiment the vector comprises a synthetic CRISPR array, an inducible promoter operably linked to the synthetic CRISPR array and a first homology arm polylinker site, wherein the synthetic CRISPR array comprises a first and second direct repeat, a first spacer polylinker site, wherein the first spacer polylinker site is located between the first and second direct repeat and a CRISPR terminator sequence located after the second direct repeat. In one embodiment first and second direct repeat independently comprise a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 2, and the CRISPR terminator sequence comprises a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 3. In one embodiment the first and second direct repeat each comprise the sequence of SEQ ID NO: 2, and the CRISPR terminator sequence comprises the sequence of SEQ ID NO: 3. In one embodiment the inducible promoter is any bacterial promoter known to those skilled in the art whose promoter activity can be regulated by one or more inducer agents. In one embodiment the inducible promoter is a lactose inducible promoter and the inducing agent is lactose or a lactose analog such as IPTG. In one embodiment the vector further comprises a native *Clostridium tyrobutyricum* Cas encoding sequence, optionally wherein the native *Clostridium tyrobutyricum* Cas encoding sequence is operably linked to an inducible promoter.

(48) The vectors described herein can be further modified for multiplex editing of multiple target sites based on the number of spacer sequences are present in the inducible CRISPR array. For example, in one embodiment a vector is provided for introducing modifications into a first and

second target genomic site of bacteria via a CRISPR-Cas complex of the present disclosure. In this embodiment a first target genomic site is a contiguous nucleic acid sequence comprising a first protospacer sequence, a first upstream sequence and first downstream sequence, and the second target genomic site is a contiguous nucleic acid sequence comprising a second protospacer sequence, a second upstream sequence and second downstream sequence, and the vector comprises a first and second homology arm polylinker site. The synthetic CRISPR array of such a vector comprises a first, second and third direct repeat, wherein the wherein the first second and third direct repeat comprises a sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 2. Optionally the first, second and third direct repeat sequence are identical to SEQ ID NO: 2. The synthetic CRISPR array further comprises a first and second spacer polylinker site, wherein the first spacer polylinker site located between the first and second direct repeat, and wherein the second spacer polylinker site located between the second and third direct repeat, optionally wherein the synthetic CRISPR array further comprises a CRISPR terminator sequence is located after the third direct repeat. In one embodiment the CRISPR terminator sequence comprises the sequence of SEQ ID NO: 3.

(49) In one embodiment the vector comprises a first spacer sequence inserted into the first spacer polylinker site and a first and second homology arm sequence inserted into the first homology arm polylinker site, wherein the first homology arm sequence comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the first upstream sequence, and the second homology arm comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the first downstream sequence. In one embodiment the spacer sequence is 10 to 100, or 20 to 60, or 20 to 50, or 25 to 50 or 30 to 40 nucleotides in length. In one embodiment the spacer comprises the sequence of SEQ ID NO: 4. In one embodiment the first homology arm sequence comprises a nucleotide sequence having 100% sequence identity to the first upstream sequence, and the second homology arm comprises a nucleotide sequence having 100% sequence identity to the first downstream sequence.

(50) In embodiments targeting two or more target protospacer sequences in a bacterial genome the vector comprises a first spacer sequence inserted into the first spacer polylinker site; a second spacer sequence of inserted into the second spacer polylinker site; a first and second homology arm sequence inserted into the first homology arm polylinker site, wherein the first homology arm sequence comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the first upstream sequence, and the second homology arm comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the first downstream sequence; and a third and fourth homology arm sequence inserted into the second homology arm polylinker site, wherein the third homology arm sequence comprises a nucleotide sequence sharing at least about first homology arm sequence comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the second upstream sequence, and the second homology arm comprises a nucleotide sequence sharing at least about 90%, 95% or 99% sequence identity to the second downstream sequence.

(51) The present disclosure further encompasses any bacterial strain comprising an inducible CRISPR array vector of the present disclosure.

(52) In accordance with one embodiment a method of producing butanol is provided wherein the method comprises the steps of culturing a *Clostridium* strain modified in accordance with the present disclosure to produce increased levels of butanol relative to the unmodified strain under conditions suitable for growth of the strain. In one embodiment the method comprises culturing the strain in the presence of a carbon source such as glucose or other sugar at a temperature at or below 37° C. In one embodiment the cells are cultured at a temperature below 37° C., optionally at a temperature selected from a range of about 20° C. to about 35° C.; or about 20° C. to about 30° C.; or about 25° C. to about 30° C.; or about 30° C., about 25° C.; or about 20° C. to about 20° C. The butanol produce by the modified cells can be collected after 48 or 72 hours of culture or longer.

(53) In accordance with one embodiment a method of modifying a target site of a bacterial cell genome is provided wherein the method comprises transforming a bacterial cell with the vector of the present disclosure and selecting for transformants comprising the vector; inducing the expression of the Type I-B CRISPR array; and identifying recombinant bacteria having a modification to the target site of the genome. Subsequent to the modification to the genome, the originally introduced vector can be eliminated from the cell. In one embodiment the introduced vector exists as an extra-chromosomal vector that is maintained in the bacterial by a selectable marker such as an antibiotic resistance gene. In one embodiment the method comprises targeting the endogenous *cat1* gene and the vector comprises a spacer sequence of

(54) TABLE-US-00002 (SEQ ID NO: 4)

CTTGTAGAAGATGGATCAACCCTACAACCTTGGA.

Example 1

Exploitation of Type I-B CRISPR-Cas of *Clostridium tyrobutyricum* for Genome Engineering

(55) The endogenous Type I-B CRISPR-Cas of *Clostridium tyrobutyricum* was analyzed for its ability to function as a tool for modifying targeted sequence present in the genome of *Clostridium tyrobutyricum*. In silico CRISPR array analysis and plasmid interference assay revealed that TCA or TCG at the 5'-end of the protospacer was the functional protospacer adjacent motif (PAM) for CRISPR targeting. With use of a lactose inducible promoter for CRISPR array expression, applicant significantly decreased the toxicity of CRISPR-Cas and enhanced the transformation efficiency of constructs that encoded the CRISPR-Cas complex. Applicants the effectiveness of the endogenous Type I-B CRISPR-Cas by successfully deleting the native *spo0A* gene with an editing efficiency of 100%. Applicant further evaluated effects of the spacer length on genome editing efficiency. Interestingly, spacers ≤ 20 nt led to unsuccessful transformation consistently, likely due to severe off-target effects; while a spacer of 30-38 nt is most appropriate to ensure successful transformation and high genome editing efficiency. Moreover, multiplex genome editing for the deletion of *spo0A* and *pyrF* was achieved in a single transformation, with an editing efficiency of up to 100%. Finally, with the integration of the aldehyde/alcohol dehydrogenase gene (*adhE1* or *adhE2*) to replace *cat1* (the key gene responsible for butyrate production and previously could not be deleted), two mutants were created for n-butanol production, with the butanol titer reached historically record high of 26.2 g/L in a batch fermentation. Altogether, these results demonstrate the programmability and high efficiency of endogenous CRISPR-Cas. The developed protocol herein has a broader applicability to other prokaryotes containing endogenous CRISPR-Cas systems. *C. tyrobutyricum* could be employed as an excellent platform to be engineered for biofuel and biochemical production using the CRISPR-Cas based genome engineering toolkit.

Materials and Methods

Bacterial Strains and Cultivation

(56) All the strains used in this study are listed in Table 3. The *E. coli* strain NEB Express (New England BioLabs Inc., Ipswich, MA) was used for general plasmid propagation. *E. coli* CA434 was employed as the donor strain for conjugation. All *E. coli* strains were routinely cultivated in Luria-Bertani (LB) broth or on solid LB agar plate supplemented with 30 $\mu\text{g/mL}$ chloramphenicol (Cm) or 50 $\mu\text{g/mL}$ kanamycin (Kan) when required. *C. tyrobutyricum* ATCC 25755 (KCTC 5387) was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and propagated anaerobically at 37° C. in Tryptone-Glucose-Yeast extract (TGY) medium. 15 $\mu\text{g/mL}$ thiamphenicol (Tm), 250 $\mu\text{g/mL}$ D-cycloserine, 40 mM lactose or 20 $\mu\text{g/mL}$ uracil was added into the medium when required.

Identification and Analysis of Putative Protospacer Matching CRISPR Spacers of *C. tyrobutyricum*

(57) Nucleotide BLAST was used to analyze the CRISPR spacers of *C. tyrobutyricum*, by aligning the spacer sequences against the existing genome sequences in the National Center for Biotechnology Information (NCBI) database. Putative protospacers were inspected for their matching with the spacers as the putative invading DNA elements, such as phage (prophage),

plasmid, transposon, integrase, and so on. For the analysis, we set a maximum of 15% (a maximum of 5/34 mismatching nucleotides) for the mismatches between the putative protospacer and the corresponding CRISPR spacer of *C. tyrobutyricum*.

Plasmid Construction

(58) All the plasmids and primers used in this study are listed in Table 3 and Table 4, respectively. The Phanta Max Super-Fidelity DNA Polymerase (Vazyme Biotech Co., Ltd., Nanjing, China) was used for the PCR to amplify DNA fragments for cloning purposes. For the attempt to delete *spo0A* gene (CTK_RS09345) in *C. tyrobutyricum* using the Type II CRISPR-Cas9 and CRISPR-Cas9 nickase (nCas9) systems derived from *S. pyogenes*, the plasmid pYW34-BtgZI was chosen as the mother vector. This vector contains the Cas9 open reading frame (ORF) driven by the lactose inducible promoter and the chimeric gRNA sequence preceded by two BtgZI sites (for easy re-targeting purpose by inserting the small RNA (sCbei_5830) promoter along with the 20-nt guiding sequence). The vector pJZ23-Cas9 was constructed from pYW34-BtgZI through Gibson Assembly as follows. The erythromycin (Erm) marker and CAK1 replicon of pYW34-BtgZI were replaced with Cm marker and pBP1 replicon, respectively, through an in vitro double digestion with Cas9 nuclease following the procedure as described previously (Wang et al., 2016, ACS Synth. Biol. 5, 721-732). The Cm marker and the pBP1 replicon were amplified from pMTL82151. The TraJ component which is essential for the conjugation was also amplified from pMTL82151 and cloned into the *ApaI* restriction site of pYW34-BtgZI through Gibson Assembly, generating vector pJZ23-Cas9. To construct pJZ58-nCas9, the Plac-Cas9 expression cassette within pJZ23-Cas9 was replaced with the Plac-nCas9 expression cassette as follows. A partial fragment of the nCas9 ORF which contains the mutation (D10A) was obtained by PCR using plasmid pMJ841 (Addgene, Cambridge, MA, USA) as the template. Then the partial fragment of nCas9 was fused with lactose inducible promoter (which was amplified from pYW34-BtgZI) through Splicing by Overlap Extension (SOE) PCR, yielding the Plac-nCas9 expression cassette. The Plac-nCas9 expression cassette was cloned into pJZ23-Cas9 by replacing the Plac-Cas9 fragment between *ApaI* and *NheI* restriction sites, generating pJZ58-nCas9.

(59) Based on pJZ23-Cas9 and pJZ58-nCas9, the small RNA (sCbei_5830) promoter fused with the 20-nt guiding sequence (5'-GACATGCTATTGAAGTAGCG-3'; SEQ ID NO: 6) targeting on *spo0A* and two homology arms (~1 kb each) were cloned into the BtgZI and *NotI* sites, respectively, as described previously (Wang et al., 2017 Appl. Environ. Microbiol. 83, e00233-17), generating pJZ23-Cas9-*spo0A* and pJZ58-nCas9-*spo0A*.

(60) In order to employ the CRISPR-AsCpf1 system derived from *Acidaminococcus* sp. BV3L6 to delete *spo0A* in *C. tyrobutyricum*, the plasmid pJZ60-AsCpf1-*spo0A* was constructed as follows. First, AsCpf1 was amplified from pDEST-hisMBP-AsCpf1-EC and fused with the lactose inducible promoter (amplified from pYW34-BtgZI) through SOE PCR, yielding the Plac-AsCpf1 expression cassette. The Plac-AsCpf1 expression cassette was then cloned into the *NdeI* restriction site of pMTL82151 with Gibson Assembly, yielding the plasmid pWH36-AsCpf1. Based on pWH36-AsCpf1, the small RNA (sCbei_5830) promoter fused with a synthetic CRISPR-AsCpf1 array and two homology arms (~1 kb each) were cloned into the *BamHI* site with Gibson Assembly, generating pJZ60-AsCpf1-*spo0A*. The synthetic CRISPR-AsCpf1 array was designed to contain two 20-nt direct repeat sequences (5'-TAATTTCTACTCTTGAGAT-3'; SEQ ID NO: 7) separated by one 23-nt guide sequence (5'-CCGAGAGTAATCGTGCTTTCAGC-3'; SEQ ID NO: 8) targeting on the *spo0A* gene. The small RNA promoter was used to drive the expression of the CRISPR-AsCpf1 array (See Wang et al., 2016).

(61) For the plasmid interference assay, the two primers (see the 'Plasmid interference assays' section in Table 4) for each plasmid (carrying the protospacer with 5' or 3' PAM) were first annealed, and then ligated into pMTL82151 which was pre-digested with *EcoRI* and *BamHI*. Plasmid pJZ69-leader-38*spo0A* was constructed through Gibson Assembly by cloning a synthetic CRISPR expression cassette and two homology arms (for *spo0A* deletion through homologous

recombination) into the vector pMTL82151 between EcoRI and KpnI sites, and between KpnI and BamHI sites, respectively. The synthetic CRISPR expression cassette contained a 291 bp native CRISPR leader sequence, a 38-nt spo0A spacer1 sequence (5'-ATACCGTTTTCTTGCTCTCACTACTATTAGCTATATCA-3') flanked by two 30-nt direct repeat sequences (5'-GTTGAACCTTAACATGAGATGTATTTAAAT-3'; SEQ ID NO: 2) and a 342 bp terminator sequence which was found at the downstream of the endogenous CRISPR array of *C. tyrobutyricum*. The leader sequence, terminator sequence, upstream and downstream homology arms (~1 kb each) of spo0A were obtained by PCR using the genomic DNA (gDNA) of *C. tyrobutyricum* as the template (Table 4). Spacer and direct repeat sequences were included in the reverse primer for amplifying the leader sequence and the forward primer for amplifying the terminator. The synthetic CRISPR expression cassette was obtained by fusing the spacer and direct repeat sequences through SOE PCR. To construct pJZ74-Plac-38spo0A and pJZ76-Para-38spo0A, a lactose inducible promoter and an arabinose inducible promoter were used respectively to replace the native leader sequence in pJZ69-leader-38spo0A. The lactose inducible promoter and arabinose inducible promoter were amplified from the plasmid pYW34-BtgZI and the gDNA of *C. acetobutylicum* ATCC 824, respectively. Based on pJZ74-Plac-38spo0A, plasmid pJZ75-Plac-38spo0A was constructed by replacing the 38-nt spo0A spacer1 sequence with the 38-nt spo0A spacer2 sequence (5'-GCAACCATAGCTATAAATTCTGAATTTGTTGGTTTACC-3'; SEQ ID NO: 10) which targeted on another locus of the spo0A gene (Table 4).

(62) Plasmids pJZ74-Plac-10spo0A, pJZ74-Plac-20spo0A, pJZ74-Plac-30spo0A and pJZ74-Plac-50spo0A (for evaluating spacers of various lengths) were constructed by replacing the 38-nt spo0A spacer1 sequence in pJZ74-Plac-38spo0A with the 10-nt spacer1 (5'-ATACCGTTTT-3'; SEQ ID NO: 11), 20-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCA-3'; SEQ ID NO: 12), 30-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCACTACTATTAG-3'; SEQ ID NO: 13), and 50-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCACTACTATTAGCTATATCATTATTAAACATT-3'; SEQ ID NO: 14), respectively.

(63) For the double deletion of the spo0A gene and pyrF gene (CTK_RS12430), the plasmid pJZ77-Plac-30spo0A/30pyrF was constructed to contain the synthetic CRISPR expression cassette comprised of the lactose inducible promoter, the native terminator and a synthetic array sequence carrying two spacer sequences insulated by three 30-nt direct repeat sequences. The synthetic CRISPR expression cassette and four homology arms (for deleting the two genes respectively) were cloned through Gibson Assembly into pMTL82151 between EcoRI and KpnI sites, and between KpnI and BamHI sites, respectively. The 30-nt spacer1 targeting on spo0A and the 30-nt spacer3 (5'-TTGGATGTTCTTATAAGGACAAATACTCCT-3'; SEQ ID NO: 15) targeting on pyrF were used in pJZ77-Plac-30spo0A/30pyrF. The upstream and downstream homology arms for spo0A deletion (~300 bp each) and for pyrF deletion (~300 bp each) respectively were amplified using the gDNA of *C. tyrobutyricum* as template (Table 4). The plasmid pJZ77-Plac-30spo0A (30-nt spacer1, two arms of ~300 bp for each) for spo0A single deletion and the plasmid pJZ77-Plac-30pyrF (30-nt spacer3, two arms of ~300 bp for each) for pyrF single deletion were constructed as the control for the double deletion using the 'two-spacer' approach.

(64) To delete the phosphotransacetylase/acetate kinase operon (pta-ack; CTK_RS08755-CTK_RS08750), plasmids pJZ86-Plac-34pta/ack was constructed by replacing the 38-nt spo0A spacer1 sequence in pJZ74-Plac-38spo0A with the 34-nt pta-ack spacer4 (5'-GATTGTGCTGTAAATCCTGTACCTAATACTGAAC-3'; SEQ ID NO: 16). Upstream and downstream homology arms (~500 bp each; containing additional KpnI and BamHI recognition sequences in the middle) for pta-ack operon deletion were amplified using the gDNA of *C. tyrobutyricum* as template (Table 4) and cloned into pMTL82151 through Gibson Assembly between KpnI and BamHI sites. The adhE1 gene (CA_P0162) and adhE2 gene (CA_P0035) amplified from the total DNA of *C. acetobutylicum* ATCC 824 was inserted into the middle of the two homology arms of plasmid pJZ86-Plac-34pta/ack between the additional KpnI and BamHI

sites, yielding pJZ86-Plac-34pta/ack(adhE1) and pJZ86-Plac-34pta/ack(adhE2), respectively. The constructions of plasmids pJZ95-Plac-34cat1, pJZ95-Plac-34cat1(adhE1) and pJZ95-Plac-34cat1(adhE2), used for cat1 gene (CTK_RS03145) deletion or replacement, were similar with plasmids pJZ86-Plac-34pta/ack, pJZ86-Plac-34pta/ack(adhE1) and pJZ86-Plac-34pta/ack(adhE2), respectively. The spacer used for targeting cat1 gene was 34-nt spacer5 (5'-CTTGTAGAAGATGGATCAACCCTACAACCTTGTA-3'; SEQ ID NO: 4). To construct the plasmid-based adhE1 or adhE2 overexpression vectors, the promoter of cat1 gene was amplified from the gDNA of *C. tyrobutyricum* and cloned into pMTL82151 through Gibson Assembly between EcoRI and KpnI sites, generating plasmid pJZ98-Pcat1. Then adhE1 gene and adhE2 gene were cloned into plasmid pJZ98-Pcat1 through Gibson Assembly between BtgZI and EcoRI sites, yielding pJZ98-Pcat1-adhE1 and pJZ98-Pcat1-adhE2, respectively.

Transformation of *C. tyrobutyricum*

(65) Plasmids used in this study were transformed into *C. tyrobutyricum* via conjugation following published protocols with modifications (Yu et al., 2012 Appl. Microbiol. Biotechnol. 93, 881-889). The donor strain *E. coli* CA434 carrying the recombinant plasmid was cultivated in LB medium supplemented with 30 µg/mL Cm and 50 µg/mL Kan. When the OD_{sub.600} reached 1.5-2.0, about 3 mL *E. coli* CA434 cells were centrifuged and washed twice (with 1 mL fresh LB medium for each wash) to remove the antibiotics. The obtained donor cells were then mixed with 0.4 mL of the recipient culture of *C. tyrobutyricum* (which had an OD_{sub.600} of 2.0-3.0 after an overnight growth in TGY medium). The cell mixture was spotted onto a well-dried TGY agar plate and incubated in the anaerobic chamber at 37° C. for mating purposes. After 24 hours, the transconjugants were collected by washing them off the conjugation plate using one mL of TGY medium, and were then spread onto TGY plates containing 15 µg/mL Tm and 250 µg/mL D-cycloserine (for eliminating the residual *E. coli* CA434 donor cells). Transformant colonies could be generally observed after 48-96 h of incubation.

Mutant Screening

(66) The screening of mutants was performed following the protocol as described previously with modifications (see Wang et al., 2017). The transformant colonies of *C. tyrobutyricum* were picked and inoculated into TGY liquid medium with addition of 15 µg/mL Tm (TGYT). The obtained cultures were then diluted serially and spread onto TGY plates supplemented with 40 mM lactose and 15 µg/mL Tm (TGYLT). The plates were incubated anaerobically at 37° C. until colonies were observed. Colony PCR (cPCR) was then performed to screen the putative mutants. When the deletion of pyrF is involved, 20 µg/mL uracil was added into TGYLT medium (TGYLTU) to support the growth of ΔpyrF strain. When shorter spacer sequence (30 bp) and shorter homology arms (~300 bp) were used for the gene deletion, a series of subculturing (1% v/v inoculum) was carried out using either TGYLT or TGYLTU liquid medium to enrich the desirable homologous recombination, before plating the culture onto the TGYLT or TGYLTU plates for selection.

Batch Fermentation

(67) Batch fermentations with various *C. tyrobutyricum* strains were carried out in 500 mL bioreactors (GS-MFC, Shanghai Gu Xin biological technology Co., Shanghai, China) with a 250 mL working volume. The fermentation medium used in this study was prepared as described previously (Zhang et al., 2017, Biotechnol. Bioeng. 114, 1428-1437), which comprised (per liter of distilled water): 110 g glucose; 5 g yeast extract; 5 g tryptone; 3 g (NH_{sub.4})_{sub.2}SO_{sub.4}; 1.5 g K_{sub.2}HPO_{sub.4}; 0.6 g MgSO_{sub.4}·7H_{sub.2}O; 0.03 g FeSO_{sub.4}·7H_{sub.2}O, and 1 g L-cysteine. The *C. tyrobutyricum* strain was first incubated anaerobically at 37° C. in TGY medium until OD_{sub.600} reached 1.5 and then the active seed culture was inoculated into the bioreactor at a volume ratio of 5%. The fermentation was carried out at pH 6.0 under various temperatures (20, 25, 30, 37° C.). Batch fermentations with *C. beijerinckii* NCIMB 8052 and *C. saccharoperbutylacetonicum* N1-4 under various temperatures (20, 25, 30, 35° C.) were carried out as described previously. Samples were taken every 12 hours for the analysis.

Analytical Methods

(68) Cell growth was determined by measuring the optical density at 600 nm (OD_{sub.600}) using a cell density meter (Ultrospec 10, Biochrom Ltd., Cambridge, England). Glucose, acetate, ethanol, butyrate and butanol concentrations in the fermentation broth were analyzed using an HPLC (Agilent 1260 series, Agilent Technologies, Santa Clara, CA, USA) equipped with a refractive index detector (RID) and an Aminex HPX-87H column (Bio-Rad, Hercules, CA, USA). 5 mM H_{sub.2}SO_{sub.4} was used as the mobile phase a flow rate of 0.6 mL/min at 25° C.

Results

Attempts of Genome Editing in *C. tyrobutyricum* with CRISPR-Cas9/Cpf1 Systems

(69) Recently, genome editing tools have been developed for several Gram-positive bacteria based on the Type II CRISPR-Cas9/nCas9 system derived from *S. pyogenes*, and various Type V CRISPR-Cpf1 systems. These systems were first considered by applicants for genome engineering in *C. tyrobutyricum*. The *spo0A* gene which is the master regulator for sporulation was selected as the target gene to delete. To abate the strong toxicity of the nuclease/nickase, we constructed CRISPR-Cas9/nCas9/AsCpf1 based vectors by placing the Cas9/nCas9/AsCpf1 encoding gene under the control of a lactose inducible promoter, whereas the gRNA/crRNA were expressed from the constitutive small RNA promoter from *C. beijerinckii*. (Wang et al., 2016) In addition, the homology arms for *spo0A* deletion through homologous recombination were inserted into the same plasmid (Wang et al., 2016). The resultant plasmid (pJZ23-Cas9-*spo0A*, pJZ58-nCas9-*spo0A* and pJZ60-AsCpf1-*spo0A*, respectively; FIG. 3A) was attempted to be transformed into *C. tyrobutyricum*. Although numerous attempts were implemented, no transformant could be obtained (FIG. 3C). This indicated that, due to the high toxicity of the heterologous nuclease/nickase and the limited transformation efficiency of *C. tyrobutyricum*, the genome editing is difficult to be realized in this microorganism with the CRISPR-Cas9/nCas9/Cpf1 system. It has been reported that the endogenous CRISPR-Cas system within bacteria and archaea can be harnessed for genome editing for the host microorganism (Li et al., 2015 Nucleic Acids Res. 44, e34). From the genome sequence, we noticed that *C. tyrobutyricum* possesses a Type I-B CRISPR-Cas system. Therefore, we next turned to exploit this endogenous CRISPR-Cas system for genome editing in *C. tyrobutyricum*.

In Silico Analysis of the Type I-B CRISPR-Cas System of *C. tyrobutyricum*

(70) Based on the genome sequence, two CRISPR arrays were identified located at two different loci within the *C. tyrobutyricum* genome. The first CRISPR array (Array1) contains 17 spacers (length: 34-38 nt) flanked by direct repeat sequences of 30 nt (5'-ATTGAACCTTAACATGAGATGTATTAAAT-3'; SEQ ID NO: 18). However, no putative Cas-encoding gene was found at the upstream or downstream of Array1. The second CRISPR array (Array2) was comprised of eight spacers (length: 34-38 nt) flanked by direct repeat sequences of 30 nt (5'-GTTGAACCTTAACATGAGATGTATTAAAT-3'; SEQ ID NO: 2) which is only one nucleotide different from that of Array1). A core cas gene operon (*cas6-cas8b-cas7-cas5-cas3-cas4-cas1-cas2*) was found at the upstream of Array2, indicating that this CRISPR-Cas system belongs to the Type I-B subtype (FIG. 1A).

(71) The CRISPR-Cas system is known as an immune system, and its spacer sequences are typically derived from the invading genetic elements during the 'adaptation' stage. Therefore, we set out to analyze all the 25 spacer sequences specified in Array1 and Array2 using Nucleotide BLAST, aiming to elucidate whether any spacer sequence matches the putative invading DNA elements, including phage (prophage), plasmid, transposon, and integrase. In order to determine the putative protospacers, a mismatch of less than 15% (5/34 mismatching nucleotides or less) was defined (Shariat et al., 2015). Among all the 25 spacers in the CRISPR-Cas system of *C. tyrobutyricum*, only one spacer sequence (the 17^{sup}.th spacer within Array 1, Array1-17: 5'-TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT-3'; SEQ ID NO: 19) hit (with five mismatches) the putative protospacers found in phage sequence from *C. thermocellum* and

prophage sequence from *Geobacillus thermoglucosidasius* (FIG. 1B).

Identification of Protospacer Adjacent Motif (PAM) Sequences

(72) A plasmid transformation interference assay was carried out to test the activity of the Type I-B CRISPR-Cas system of *C. tyrobutyricum* and meanwhile identify the putative PAM sequences. The plasmid employed in interference assay contains a protospacer for the DNA targeting purpose and a 5-nt putative PAM sequence located at the 5'- or 3'-end of the protospacer which is essential for the recognition by the Type I CRISPR-Cas system (Table 1). Though the spacer Array1-17 was the only spacer found to match the invading DNA elements, there was no adjacent Cas-encoding genes associated with Array1 discovered. Therefore, additionally we decided to employ another spacer (Array2-1:

(73) TABLE-US-00003 SEQ ID NO: 21)

GCATTCAGACTTGCAACTGTAAGTCCCTAGTACTCCCC;

derived from Array2 as the protospacer for the plasmid interference purpose. The 5-nt sequences derived from the upstream or downstream of identified putative protospacers were tested as putative PAM sequences (FIG. 1B & Table 1). Our in silico analysis revealed that the *C. tyrobutyricum* CRISPR array possessed high homology to the CRISPR array of *C. pasteurianum*, for both the leader and direct repeat sequences (FIGS. 6A & 6B). Therefore, we hypothesized that the CRISPR-Cas system of *C. tyrobutyricum* may share the same or similar PAM with that of *C. pasteurianum*. Hence, the PAM sequences for *C. pasteurianum* Type I-B CRISPR-Cas system were also employed in the plasmid interference assay (Table 1). Altogether, 14 interference plasmids were constructed by combining different protospacer and PAMs (Table 1). Since both a protospacer and PAM sequence have been included on the interference plasmid, there would be no transformants (the specific plasmid is cleaved and eliminated; we define this as the 'interference response') if the CRISPR-Cas system is functional with a particular combination of the protospacer and PAM. As shown in Table 1, no matter what PAM sequences were employed, there was no interference response observed when the protospacer Array1-17 was used. This result suggests that Array1 which does not have an adjacent cas gene operon may be silent in the genome of *C. tyrobutyricum*, or it was possibly derived from a gene transfer event which was unrelated to the development of the CRISPR-Cas immunity system in *C. tyrobutyricum*. While combinations of protospacer Array2-1 with 5' adjacent PAM sequences 5'-CATCA-3' or 5'-TTTCA-3', derived from *C. tyrobutyricum* and *C. pasteurianum* respectively, successfully triggered the interference response (Table 1). Plasmids contained combinations of Array2-1 (as the protospacer) and other PAMs were transformed efficiently into *C. tyrobutyricum* (Table 1). These results indicated that Array2 along with the associated core cas gene operon in *C. tyrobutyricum* is active and highly functional. Furthermore, the specific PAM sequence located at the 5'-end of the protospacer is essential for the target recognition of Cas proteins.

We used 5-nt PAM sequences in the plasmid transformation interference assay on the basis that most identified PAMs within various microorganisms vary between 2-5 nt (Shah et al., 2013). However, it is noteworthy that the two functional PAM sequences contain a conserved 3-nt sequence 5'-TCA-3' which may play the critical role for the target recognition for *C. tyrobutyricum* Type I-B CRISPR-Cas system. To test our hypothesis, various PAMs (5'-NTCA-3' with point mutations at different positions) built upon 5'-TCA-3' were systematically evaluated for their functionality (FIG. 2). As shown in FIG. 2B, significant differences in the transformation efficiency were observed with plasmids containing different PAMs (along with Array2-1 as the protospacer). All the plasmids contained point mutations at position -4 triggered the interference response, suggesting that the first three nucleotides (5'-TCA-3') encompass the core PAM sequence. When 'T' located at position -3 was mutated, only slightly increased transformation efficiency was obtained, indicating that the nucleotide on position -3 had a minor effect on target recognition. Nevertheless, high transformation efficiency (comparable to the control plasmid pMTL82151) was observed when 'C' located at position -2 was mutated to 'G' or 'A' or 'A' located at position -1

was mutated to 'T'. The transformation efficiency was slightly increased (compared to that with 5'-NTCA-3') when 'A' located at position -1 was mutated to 'C', while 'TCG' kept the similar level of transformation efficiency with 5'-NTCA-3'. These data demonstrated that, for the appropriate function of the PAM sequence, pyrimidine nucleotides ('C' and 'T'), rather than purine nucleotides ('G' and 'A'), are more preferable at the position -2, and conversely, purine nucleotides are better options than pyrimidine nucleotides at the position -1. Overall, 3-nt sequences 5'-TCA-3' (TCA) and 5'-TCG-3' (TCG) (also written as TCR collectively for both) which led to an approximately 1,000-fold drop in plasmid transformation efficiency (compared to the control plasmid pMTL82151, FIG. 2B) were concluded to be the functional PAM sequences of the Type I-B CRISPR-Cas system in *C. tyrobutyricum*.

(74) TABLE-US-00004 TABLE 1 Effect of different combinations of protospacers and PAM sequences on the transformation efficiency. Transform efficiency ($\times 10^{\text{sup.2}}$ CFU/mL Plasmid 5' PAM Protospacer.^{sup.a} 3' PAM donor).^{sup.b} pMTL82151 4.9 ± 0.6 pIF-1 CATCT TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) 4.2 ± 0.8 pIF-2 CATCA TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) 3.7 ± 0.4 pIF-3 TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) AGGAT 4.8 ± 0.1 pIF-4 TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) CGGAT 4.2 ± 0.7 pIF-5 AATTG TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) 3.9 ± 0.5 pIF-6 TTTCA TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) 3.3 ± 0.4 pIF-7 TATCT TGGTATCACCAACTTTTGTCCAGGATATATGAGGTT (SEQ ID NO: 19) 5.1 ± 0.2 pIF-8 CATCT GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) 3.8 ± 0.3 pIF-9 CATCA GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) 0 ± 0 pIF-10 GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) AGGAT 3.5 ± 0.9 pIF-11 GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) CGGAT 4.1 ± 0.1 pIF-12 AATTG GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) 4.0 ± 0.7 pIF-13 TTTCA GCATTCAGACTTGCAACTGTAACCTCCCTAGTACTCCCC (SEQ ID NO: 22) 0 ± 0 .^{sup.a}Two kinds of protospacers were used here: Array1-17 and Array2-1).^{sup.b}Values are average \pm standard deviation based on at least two independent replicates.

Development of an Inducible CRISPR-Cas System for Genome Editing in *C. tyrobutyricum*

(75) After establishing that the endogenous Type I-B CRISPR-Cas system of *C. tyrobutyricum* was functional and had high interference activity against plasmids possessing proper protospacer and PAM sequences, we then attempted to engineer this system to be a genome editing tool for *C. tyrobutyricum*. Two parts are required for such a system: 1) a synthetic CRISPR expression cassette, containing a spacer targeting on the specific genome sequence; 2) gene editing cassette, comprised of a pair of homology arms to achieve homologous recombination (FIG. 3A). The *spo0A* gene was selected as the first target gene to be deleted. The 816 bp *spo0A* ORF contains a total of 28 potential PAMs (TCR) including 24 TCA and 4 TCG. One of the PAM (TCA) along with its downstream protospacer sequence (38-nt *spo0A* spacer1) was selected as the target site. Plasmid pJZ69-leader-38*spo0A*, comprised of a synthetic CRISPR expression cassette and a *spo0A* editing cassette (upstream and downstream homology arms, ~1 kb each), was constructed to delete the *spo0A* gene in *C. tyrobutyricum*. In the synthetic CRISPR expression cassette (SEQ ID NO: 4) comprising the native CRISPR leader (SEQ ID NO: 1) and terminator sequences (SEQ ID NO: 3) were used to drive the transcription of synthetic CRISPR array which contained the 38-nt *spo0A* spacer1 (SEQ ID NO: 9) (flanked by 30-nt direct repeat sequences (SEQ ID NO: 2). Conjugation was carried out. However, no transformants were obtained with pJZ69-leader-38*spo0A*, although the expected transformation efficiency was obtained with pMTL82151 as the control. Many

attempts have been conducted, and the results were consistently the same (data not shown). (76) Therefore, even with the endogenous CRISPR-Cas system, the instant expression could be highly toxic to the cells and thus no transformants could be obtained. Generally, the leader sequence of the CRISPR array contains a promoter for CRISPR array transcription and a regulatory signal for the uptake of new spacer-repeat elements. In this study, however, for the genome editing purposes, only the promoter function of the leader sequence is needed. In order to reduce the toxicity of endogenous CRISPR-Cas system, a lactose inducible promoter and an arabinose inducible promoter were evaluated for the transcription of the synthetic CRISPR array in place of the native leader sequence (FIGS. 3A & B). The resultant plasmids pJZ74-Plac-38spo0A and pJZ76-Para-38spo0A were transformed into *C. tyrobutyricum*. Transformants were generated with pJZ74-Plac-38spo0A, with an overall transformation efficiency of 1.7 CFU/mL donor (FIG. 3C); while the transformation with pJZ76-Para-38spo0A failed, suggesting that the arabinose inducible promoter was less stringent than the lactose inducible promoter for the expression of the CRISPR array in *C. tyrobutyricum* (FIG. 3C). As a control (or as a means to further confirm the appropriate PAM sequence), a 38-nt spo0A spacer2 (corresponding PAM: TCT) was employed to replace the 38-nt spo0A spacer1 in pJZ74-Plac-38spo0A, generating plasmid pJZ75-Plac-38spo0A. Results demonstrated that the transformation efficiency with pJZ75-Plac-38spo0A (~18.2 CFU/mL donor) increased more than an order of magnitude compared to that with pJZ74-Plac-38spo0A (FIG. 3C). The obtained transformants (with either pJZ74-Plac-38spo0A or pJZ75-Plac-38spo0A) were cultivated in TGYT medium, and then spread onto TGYLT plates to induce the expression of the synthetic CRISPR array. Colony PCR was carried out with randomly picked colonies to screen the spo0A deletion mutants. Results showed that one out of fifteen (6.7%) of the tested colonies was spo0A deletion mutant (Δ spo0A) from the transformants with pJZ75-Plac-38spo0A (FIG. 3D). While all tested colonies were Δ spo0A mutants from the transformants with pJZ74-Plac-38spo0A, representing an editing efficiency of 100% (FIG. 3D). These results confirmed our above conclusion concerning the PAM sequence: the targeting efficiency of TCA is much higher than TCT. The Δ spo0A mutant was further verified by Sanger sequencing (data not shown). Collectively, we proved that with the inducible endogenous CRISPR-Cas system, efficient genome editing could be achieved in *C. tyrobutyricum*.

Effects of Spacer Length on Transformation Efficiency and Genome Editing Efficiency

(77) In the *C. tyrobutyricum* genome, a total of 25 spacer sequences were identified in Array1 and Array2 with lengths ranging from 34 to 38 nt. In order to mimic the feature of the native Type I-B CRISPR array, the 38-nt spo0A spacer1 was employed to develop the genome editing platform for the deletion of spo0A. However, it is reasonable to question whether the length of the spacer has an effect on the transformation efficiency and genome editing efficiency of the CRISPR-Cas genome engineering platform. To answer this question, we replaced the 38-nt spo0A spacer1 in plasmid pJZ74-Plac-38spo0A with 10 nt, 20 nt, 30 nt, and 50 nt of spo0A spacer1 (while the PAM sequence TCA was kept the same), yielding pJZ74-Plac-10spo0A, pJZ74-Plac-20spo0A, pJZ74-Plac-30spo0A, and pJZ74-Plac-50spo0A, respectively (FIG. 3B). Surprisingly, no transformant was obtained after several attempts with pJZ74-Plac-10spo0A or pJZ74-Plac-20spo0A. This might be because the shorter spacer sequences (≤ 20 nt) led to severe off-target effects which killed the host cells (FIG. 3C). However, when 30-nt, 38-nt and 50-nt spacers were used, transformation efficiencies of 103.0 CFU/mL donor, 1.7 CFU/mL donor and 0.2 CFU/mL donor were obtained, respectively (FIG. 3C). The longer spacers can bind more tightly to the target and thus increase the self-targeting activity of the endogenous CRISPR-Cas system, which may contribute to the decreased transformation efficiency. The genome editing efficiency was also assessed for the transformants obtained with pJZ74-Plac-30spo0A, pJZ74-Plac-38spo0A or pJZ74-Plac-50spo0A. Interestingly, colonies of various sizes were observed for the transformants harboring pJZ74-Plac-30spo0A on the TGYLT plates, while the colonies from the other two transformants appeared homogeneous in sizes. Large and small colonies of the transformant harboring pJZ74-Plac-

30spo0A were picked separately to screen for the Δspo0A mutant, and editing efficiencies of 93.3% and 13.3% were obtained, respectively. The different genome editing efficiency for large and small colonies might be due to the low self-targeting activity of the endogenous CRISPR-Cas system when 30-nt spacer was employed. In this case, some of the host cells could survive from the selection of the endogenous CRISPR-Cas system, but their growth was still inhibited. Most of the observed small colonies were wild type cells with growth inhibited, whereas most of the large colonies were mutant cells without growth interference because their target site for the CRISPR-Cas system had been eliminated. On the other hand, the editing efficiencies of transformants obtained with pJZ74-Plac-38spo0A or pJZ74-Plac-50spo0A were both 100% (FIG. 3D).

Multiplex Genome Engineering

(78) As described above, single gene deletion was achieved with high efficiency using the inducible endogenous CRISPR-Cas system. Here, we further explored this system for multiplex genome editing in *C. tyrobutyricum*. The pyrF gene encoding the enzyme orotidine 5-phosphate decarboxylase (involved in the de novo pyrimidine biosynthesis) together with the spo0A gene were selected as targets to delete. In order to have the CRISPR-Cas system target onto two loci at the same time, we inserted two spacers targeting on spo0A and pyrF respectively into the same CRISPR array insulated by three direct repeats (FIG. 4A). Considering that the longer spacer is more toxic to the host cells as we demonstrated above, 30 nt was used for both spacers (spo0A spacer1 and pyrF spacer3). In addition, as we noticed that, with the increase of the plasmid size, the transformation efficiency decreases dramatically (especially when the vector size >10 kb; data not shown), we used shorter homology arms for the deletion of both genes (two homology arms for the deletion of each gene, with the length of each arm is ~300 bp), to keep the final vector size <9 kb (FIG. 4A). Control plasmids pJZ77-Plac-30spo0A and pJZ77-Plac-30pyrF were also constructed for deleting spo0A and pyrF individually by using the same corresponding modules (spacer and homology arms) in pJZ77-Plac-30spo0A/30pyrF for deleting spo0A and pyrF, respectively. The three plasmids were successfully transformed into *C. tyrobutyricum*, and the resulting transformants were then spread onto TGYLTU plates. However, no mutant was detected (47 colonies from each transformant were screened with cPCR) for any of the three transformants, which was not surprising considering the reduced editing efficiency when shorter spacers and homology arms were used. In order to enrich the desirable homologous recombination, a series of subculturing was performed in TGYLTU liquid medium. Then mutant screening was performed with cPCR for the 8.sup.th and 15.sup.th generations of the subculture. For the 8.sup.th generation, for spo0A and pyrF deletion respectively, editing efficiencies of 59.6% and 40.4% were obtained with the one-spacer approach (using pJZ77-Plac-30spo0A and pJZ77-Plac-30pyrF, respectively), while editing efficiencies of 53.2% and 31.9% were obtained with the two-spacer approach (using pJZ77-Plac-30spo0A/30pyrF) (FIG. 4B). In addition, double deletion was also detected with the two-spacer approach, but at a much lower rate (6.4%) (FIG. 4B). For the 15.sup.th generation, up to 100% editing efficiencies were observed for spo0A and pyrF deletion with both one-spacer and two-spacer approaches, which meant that as high as 100% editing efficiency for the double deletion was also achieved with the two-spacer approach (FIG. 4C).

Engineered *C. tyrobutyricum* for Butanol Production

(79) *C. tyrobutyricum* is a hyper-butyrate producer, indicating that the metabolic pathway from glucose to butyryl-CoA is highly favorable (FIG. 5). Therefore, using the high efficient endogenous CRISPR-Cas system, we attempted to engineer the *C. tyrobutyricum* for hyper-butanol production. Two aldehyde/alcohol dehydrogenase genes (adhE1 and adhE2) which can convert butyryl-CoA to butanol were chosen to introduce into *C. tyrobutyricum*. In order to drive more metabolic flux towards C4 products, the pta-ack operon which was responsible for acetate formation was initially selected to be deleted or replaced by adhE1/adhE2 (FIG. 5). However, none of the attempts was successful (data not shown), suggesting that the pta-ack operon was vital for *C. tyrobutyricum* metabolism and thus cannot be deleted.

(80) In *C. tyrobutyricum*, cat1 is the essential gene for butyrate biosynthesis, and the ptb-buk operon as seen in solventogenic clostridial strains does not exist (FIG. 5). Therefore, we hypothesized that deletion of cat1 could eliminate butyrate production, and thus the introduction of adhE1/adhE2 can lead to the conversion of butyryl-CoA for enhanced butanol production. However, it was previously reported that the disruption of cat1 was not achievable (with the mobile group II intron), because the inactivation of cat1 could likely lead to the inability of the strain for NADH oxidization (Lee et al., 2016a, mBio 7, e00743-16). Here, based on the high efficient CRISPR-Cas system for genome engineering, we attempted to delete the cat1 gene or replace it with adhE1 or adhE2. Similar as the previous report, the deletion of cat1 was fruitless despite numerous attempts, however the replacement of cat1 with adhE1 or adhE2 was successful, yielding mutants $\Delta cat1::adhE1$ and $\Delta cat1::adhE2$, respectively. As the control, the recombinants WT(pJZ98-Pcat1-adhE1) and WT(pJZ98-Pcat1-adhE2) were also obtained by introducing the plasmid-based adhE1 and adhE2 (driven by the cat1 promoter) overexpression vectors into *C. tyrobutyricum*. Initial batch fermentations were carried out at 37° C. (the optimum temperature for the cell growth of *C. tyrobutyricum*). Results demonstrated that acetate (14.8 g/L), ethanol (9.7 g/L) and butanol (8.7 g/L) were the major products with a low level of butyrate (1.3 g/L) produced for the control strain WT(pJZ98-Pcat1-adhE1) (Table 2 and FIG. 7A). However, for WT(pJZ98-Pcat1-adhE2), acetate (6.9 g/L), ethanol (7.4 g/L) and butyrate (34.1 g/L) were the major products, with only a small amount of butanol (2.0 g/L) was produced (Table 2 and FIG. 8A). As we expected, with the butyrate biosynthesis pathway replaced with the butanol producing pathway, mutants $\Delta cat1::adhE1$ and $\Delta cat1::adhE2$ produced negligible butyrate (0.6-0.8 g/L) but high levels of butanol (15.0 g/L). In addition, significant amounts of acetate (15.1-20.8 g/L) and ethanol (5.2-5.3 g/L) were also produced by the two mutants (Table 2 and FIGS. 7B & 8B).

Enhance Butanol Production by Carrying Out Fermentation at Low Temperatures

(81) It is well known that the limited butanol tolerance of the host is a major bottleneck for butanol production in microorganisms. Recent studies showed that lower temperature could alleviate the alcohol toxicity and thus increase the alcohol production. Therefore, batch fermentations were further carried out at 30, 25 and 20° C. with $\Delta cat1::adhE1$ and $\Delta cat1::adhE2$, respectively. As seen in Table 2 and FIGS. 7B-7E & 8B-8E, the acetate production was kept at the similar levels at different temperatures. However, the production of ethanol and butanol was significantly increased at these lower temperatures. Butanol titers for $\Delta cat1::adhE1$ and $\Delta cat1::adhE2$ obtained at 20° C. were 21.4 and 26.2 g/L, respectively, which increased by 42.7% and 74.7%, respectively, compared with that obtained at 37° C. While the total BE (butanol and ethanol) production of $\Delta cat1::adhE1$ and $\Delta cat1::adhE2$ reached the maximum of 35.6 and 38.2 g/L, respectively at 25° C.

(82) TABLE-US-00005 TABLE 2 Summary of fermentation results for *C. tyrobutyricum* mutants at various temperatures. sup.a

Tem	Glucose	BE yield	perature	consumption	Acetate	Butyrate	Ethanol	Butanol	Total BE
(° C.)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
WT 37	79.1	14.8	1.3	9.7	8.7	18.4	0.23		
(pJZ98-Pcat1-adhE1) WT 37	109.0	6.9	34.1	7.4	2.0	9.4	0.09		
(pJZ98-Pcat1-adhE2) $\Delta cat1::adhE1$ 37	87.1	20.8	0.6	5.3	15.0	20.3	0.23		
$\Delta cat1::adhE2$ 37	75.5	15.1	0.8	5.2	15.0	20.2	0.27		
$\Delta cat1::adhE1$ 30	109.6	22.5	0.8	14.3	17.2	31.5	0.29		
$\Delta cat1::adhE2$ 30	96.7	12.3	1.3	10.8	21.1	31.9	0.33		
$\Delta cat1::adhE1$ 25	111.9	22.8	1.3	16.6	19.0	35.6	0.32		
$\Delta cat1::adhE2$ 25	109.4	13.9	1.8	12.8	25.4	38.2	0.35		
$\Delta cat1::adhE1$ 20	111.9	21.8	1.6	10.4	21.4	31.8	0.28		
$\Delta cat1::adhE2$ 20	112.2	15.2	2.4	8.9	26.2	35.1	0.31		

sup.a The fermentation profiles are provided in FIGS. 7A-7E & 8A-8E; values are based on at least two independent replicates.

(83) TABLE-US-00006 TABLE 3 Bacterial strains and plasmids used in Example 1

Strains/Plasmids	Relevant characteristic	Sources
<i>E. coli</i> NEB Express fhuA2		
[lon] ompT gal sulA11 R(mcr-73::miniTn10-- New Tet.sup.S)2 [dcm] R(zgb-210::Tn10--Tet.sup.S) endA1		England
Δ (mcrC-mrr)114::IS10		BioLabs
CA434 hsd20(r.sup.B-, m.sup.B-), recA13, rpsL20, leu, proA2, with (Williams IncPb conjugative plasmid R702 et al., 1990)		
<i>C. tyrobutyricum</i> ATCC 25755		KCTC 5387, wild type stain ATCC

Δspo0A Derived from ATCC 25755, with spo0A gene deleted This work ΔpyrF
 Derived from ATCC 25755, with pyrF gene deleted This work Δspo0AΔpyrF
 Derived from ATCC 25755, with spo0A and pyrF This work genes deleted
 WT(pJZ98-Pcat1- Derived from ATCC 25755, harboring plasmid This work adhE1)
 pJZ98-Pcat1-adhE1 WT(pJZ98-Pcat1- Derived from ATCC 25755, harboring plasmid
 This work adhE2) pJZ98-Pcat1-adhE2 Δcat1::adhE1 Derived from ATCC 25755, cat1
 was replaced with This work adhE1 Acat1::adhE2 Derived from ATCC 25755, cat1
 was replaced with This work adhE2 Plasmids pYW34-BtgZI CAK1 ori, ColE1 ori,
 Amp.sup.R, Erm.sup.R, Plac-Cas9, (Wang et al., 2016) pJZ23-Cas9 pYW34-
 BtgZI derivative; pBP1 ori, ColE1 ori, This work Amp.sup.R, Cm.sup.R, TraJ,
 Plac-Cas9, gRNA pJZ23-Cas9-spo0A pJZ23-Cas9 derivative; 20 nt-gRNA targeting on
 This work spo0A; two homology arms (~1 kb each) pJZ58-nCas9 pJZ23-Cas9
 derivative; Plac-nCas9 This work pJZ58-nCas9-spo0A pJZ58-nCas9 derivative; 20 nt-
 gRNA targeting on This work spo0A; two homology arms (~1 kb each)
 pMTL82151 pBP1 ori, Cm.sup.R, ColE1 ori, TraJ (Heap et al., 2009) pWH36-AsCpf1
 pMTL82151 derivative; Plac-AsCpf1 This work pJZ60-AsCpf1- pWH36-AsCpf1
 derivative; 23 nt-crRNA targeting This work spo0A on spo0A; two homology
 arms (~1 kb each) pIF-1 pMTL82151 derivative; protospacer Array 1-17 This work
 flanked by 5' PAM sequence: 5'-CATCT-3' pIF-2 pMTL82151 derivative;
 protospacer Array 1-17 This work flanked by 5' PAM sequence: 5'-CATCA-3' pIF-3
 pMTL82151 derivative; protospacer Array 1-17 This work flanked by 3' PAM
 sequence: 5'-AGGAT-3' pIF-4 pMTL82151 derivative; protospacer Array 1-17 This
 work flanked by 3' PAM sequence: 5'-CGGAT-3' pIF-5 pMTL82151 derivative;
 protospacer Array 1-17 This work flanked by 5' PAM sequence: 5'-AATTG-3' pIF-6
 pMTL82151 derivative; protospacer Array 1-17 This work flanked by 5' PAM
 sequence: 5'-TTTCA-3' pIF-7 pMTL82151 derivative; protospacer Array 1-17 This
 work flanked by 5' PAM sequence: 5'-TATCT-3' pIF-8 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 5' PAM sequence: 5'-CATCT-3' pIF-9
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-CATCA-3' pIF-10 pMTL82151 derivative; protospacer Array2-1 This work
 flanked by 3' PAM sequence: 5'-AGGAT-3' pIF-11 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 3' PAM sequence: 5'-CGGAT-3' pIF-12
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-AATTG-3' pIF-13 pMTL82151 derivative; protospacer Array2-1 This work
 flanked by 5' PAM sequence: 5'-TTTCA-3' pIF-14 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 5' PAM sequence: 5'-TATCT-3' pIF-15
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-GTCA-3' pIF-16 pMTL82151 derivative; protospacer Array2-1 This work
 flanked by 5' PAM sequence: 5'-CTCA-3' pIF-17 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 5' PAM sequence: 5'-AACA-3' pIF-18
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-AGCA-3' pIF-19 pMTL82151 derivative; protospacer Array2-1 This work
 flanked by 5' PAM sequence: 5'-ACCA-3' pIF-20 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 5' PAM sequence: 5'-ATGA-3' pIF-21
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-ATTA-3' pIF-22 pMTL82151 derivative; protospacer Array2-1 This work
 flanked by 5' PAM sequence: 5'-ATAA-3' pIF-23 pMTL82151 derivative;
 protospacer Array2-1 This work flanked by 5' PAM sequence: 5'-ATCC-3' pIF-24
 pMTL82151 derivative; protospacer Array2-1 This work flanked by 5' PAM
 sequence: 5'-ATCG-3' pJZ69-leader- pMTL82151 derivative; Type I-B CRISPR

genome This work 38spo0A editing plasmid containing the native leader and terminator sequences, the synthetic CRISPR array possessed a 38 nt spacer1 (5'-ATACCGTTTTCTTGCTCTCACTACTATTAGCTA TATCA-3') targeting on the spo0A gene, and two homology arms (~1 kb each) for spo0A deletion pJZ74-Plac-38spo0A Same as pJZ69-leader-38spo0A, except that a This work lactose inducible promoter (instead of the native leader sequence) was used to drive the transcription of the CRISPR array pJZ75-Plac-38spo0A Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 38-nt spacer2 (5'-GCAACCATAGCTATAAATTCTGAATTTGTTGG TTTACC-3') pJZ76-Para- Same as pJZ74-Plac-38spo0A, except that the This work 38spo0A lactose inducible promoter was replaced with an arabinose inducible promoter pJZ74-Plac-10spo0A Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 10-nt spacer1 (5'-ATACCGTTTT-3') pJZ74-P/ac-20spo0A Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 20-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCA-3') pJZ74-Plac-30spo0A Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 30-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCACTACTATTAG-3') pJZ74-Plac-50spo0A Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 50-nt spacer1 (5'-ATACCGTTTTCTTGCTCTCACTACTATTAGCTA TATCATTATTAAACATT-3') pJZ77-Plac-30spo0A Same as pJZ74-Plac-30spo0A, except that ~300 bp This work homology arms were used (instead of ~1 kb arms) pJZ77-Plac-30pyrF Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 30-nt spacer3 (5'-TTGGATGTTCTTATAAGGACAAATACTCCT-3') targeting on the pyrF gene and the homology arms for spo0A deletion were replaced with the homology arms (~300 bp each ×2) for pyrF deletion pJZ77-Plac- Combined pJZ77-Plac-30spo0A and pJZ77-Plac- This work 30spo0A/30pyrF 30pyrF, including the 30-nt spacer1 targeting on the spo0A gene, the 30-bp spacer3 targeting on the pyrF gene, the homology arms (~300 bp each ×2) for spo0A deletion and the homology arms (~300 bp each ×2) for pyrF deletion pJZ86-Plac- Same as pJZ74-Plac-38spo0A, except that the 38-nt This work 34pta/ack spacer1 was replaced with the 34-nt spacer4 (5'-GATTGTGCTGTAAATCCTGTACCTAATACTGA AC-3') targeting on the pta-ack operon and the homology arms for spo0A deletion were replaced with the homology arms (~500 bp each ×2) for pta-ack deletion pJZ86-Plac- pJZ86-Plac-34ptalack derivative; adhE1 was This work 34pta/ack(adhE1) inserted between the two homology arms pJZ86-Plac- pJZ86-Plac-34pta/ack derivative; adhE2 was This work 34pta/ack(adhE2) inserted between the two homology arms pJZ95-Plac-34cat1 Same as pJZ74-Plac-38spo0A, except that the 38-nt This work spacer1 was replaced with the 34-nt spacer5 (5'-CTTGTAGAAGATGGATCAACCCTACAACCTTG GTA-3'; SEQ ID NO: 4) targeting on the cat1 gene and the homology arms for spo0A deletion were replaced with the homology arms (~500 bp each ×2) for cat1 deletion pJZ95-Plac- pJZ95-Plac-34cat1 derivative; adhE1 was inserted This work 34cat1(adhE1) between the two homology arms pJZ95-Plac- pJZ95-Plac-34cat1 derivative; adhE2 was inserted This work 34cat1(adhE2) between the two homology arms pJZ98-Pcat1 pMTL82151 derivative; containing cat1 promoter This work pJZ98-Pcat1-adhE1 pJZ98-Pcat1 derivative; plasmid-based adhE1 gene This work overexpression driven by the cat1 gene promoter pJZ98-Pcat1-adhE2 pJZ98-Pcat1 derivative; plasmid-based adhE2 gene This work overexpression driven by the cat1 gene promoter

spo0A deletion using CRISPR-Cas9 or CRISPR-nCas9 system Cm marker 5'-ACAATTGAATTTAAAAGAAACCGATAGGCCGGCCAGTGGGCAA GTTG-3' (SEQ ID NO: 26) 5'-CTTTAGTAACGTGTAACCTTTCCAAATGGAGTTTAAACTTAGGGT AAC-3' (SEQ ID NO: 27) in vitro Cas9 5'-AAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGG nuclease ACTAGCCTTATTTTAACTT GCTATTTCTAGCTCTAAAAC-3' (SEQ ID double NO: 28) digestion of 5'-AGAAATTAATACGACTCACTATAGGGATACTAAAACCTGAATTGA CAK1 TTGTTTTAGAGCTAGAAAT AGCAAGTTAAAATAAGG-3' (SEQ ID NO: 29) 5'-AGAAATTAATACGACTCACTATAGGGAGTGCAAAAAAAGATAT AATGTTTTAGAGCTAGAAAT AGCAAGTTAAAATAAGG-3' (SEQ ID NO: 30) pBP1 replicon 5'-CGAACACGAACCGTCTTATCTCCCATTGTTCTGAATCCTTAGCTA ATGG-3' (SEQ ID NO: 31) 5'-TAATGACCCCGAAGCAGGGGGCCCAATGAATTTGTAAATAAAC CACAAAC-3' (SEQ ID NO: 32) TraJ 5'-GTAATACTAAAACCTGAATTGATTCCTGCTTCGGGGTTCATTATAG-3' (SEQ ID NO: 33) 5'-ATCAAGTAAATAAACCAAGTATATAAGGGCCCGATCGGTCTTGC CTTGCTCGTCG-3' (SEQ ID NO: 34) PsRNA + 20 5'-AAAGTTAAAAGAAGAAAATAGAAATATAATCTTTAATTTGAAA nt AGATTTAAG-3' (SEQ ID NO: 35) protospacer 5'-TTGCTATTTCTAGCTCTAAAACCGCTACTTCAATAGCATGTCATG sequence GTGGAATGATAAGGG-3' (SEQ ID NO: 36) Homology 5'-CTTTGTGATATGACTAATAATTAGCGGCCGCCTCAGGGTGTATT arms (~1 kb AGTTGTAG-3' (SEQ ID NO: 37) each) 5'-GTTAACCATTGATATCACTTTAATATTTTACTCCCCTTTTATT-3' (SEQ ID NO: 38) 5'-AATAAAAGGGGAGTAAAATATTAAAGTGATATCAATGGTTAAC-3' (SEQ ID NO: 39) 5'-ATCCACTAGTAACCATCACACTGGCGGCCGCGACCAATACTGAA CTATGACC-3' (SEQ ID NO: 40) Plac-nCas9 5'-CACCGACGAGCAAGGCAAGACCGATCGGGCCCTTATATACTTGG TTTATTTACTTG-3' (SEQ ID NO: 41) 5'-CCTATTGAGTATTTCTTATCCATTTTCAGCCCTCCTGTGAAATTG-3' (SEQ ID NO: 42) 5'-CAATTTACAGGAGGGCTGAAATGGATAAGAAATACTCAATA GG-3' (SEQ ID NO: 43) 5'-GATAAATTTATAAAATTCTTCTTGGC-3' (SEQ ID NO: 44) spo0A deletion using CRISPR-AsCpf1 system Plac-AsCpf1 5'-GGAAACAGCTATGACCGCGGCCGCTGTATCTTATATACTTGGTT TATTTACTTGATTATT-3' (SEQ ID NO: 45) 5'-TGGTAGAGATTGGTGAAGCCTTCAAACCTGTGTCAATTCAGCCCT CCTGTGAAATTGTTATCCG CTCACAA-3' (SEQ ID NO: 46) 5'-TTGTGAGCGGATAACAATTCACAGGAGGGCTGAAATGACACAG TTTGAAGGCTTCACCAAT CTCTACCA-3' (SEQ ID NO: 47) 5'-GGGTACCGAGCTCGAATTCGTAATCATGGTTTAGTTTCTCAGTTC TTGAATGTAGGCCAG-3' (SEQ ID NO: 48) PsRNA- 5'-GATTACGAATTCGAGCTCGGTACCCGGGATAATCTTTAATTTGA crRNA AAAGATTTAAG-3' (SEQ ID NO: 49) 5'-TTAGCTGAAAGCACGATTACTCTCGGATCTACAAGAGTAGAAAT TAATGGTGG-3' (SEQ ID NO: 50) Homology 5'- arms (~1 kb GATCCGAGAGTAATCGTGCTTTTCAGCTAATTTCTACTCTTGTAGATC each) TCAGGGTGTATTAGTTG TAG-3' (SEQ ID NO: 51) 5'-CCATGGACGCGTGACGTCGACTCTAGAGGACCAATACTGAACCTA TGACC-3' (SEQ ID NO: 52) spo0A deletion using endogenous Type I-B CRISPR-Cas system Leader + 38- 5'-CTGTATCCATATGACCATGATTACGTAAGATCGTAGCAGATAAG nt

spacer1 + GAT-3' (SEQ ID NO: 53) terminator 5'-
 GCTAATAGTAGTGAGAGCAAGAAAACGGTATATTTAAATACATC
 TCATGTTAAGGTTCAAC CTGTGTAAAATAGCCATTC-3' (SEQ ID NO: 54) 5'-
 TTTCTTGCTCTCACTACTATTAGCTATATCAGTTGAACCTTAACA
 TGAGATGTATTTAAATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 55) 5'-
 CTACAATAACACCCCTGAGGGTACCTGGAGATATAATAAGCT ATGCC-3' (SEQ ID
 NO: 56) Homology 5'-CATGATTACGAATTCGAGCTCGGTACCCTCAGGGTGTATTAGTT
 arms (~1 kb GTAG-3' (SEQ ID NO: 57) each) 5'-
 GTTAACCATTGATATCACTTTAATATTTTACTCCCCTTTTATT-3' (SEQ ID NO: 58) 5'-
 AATAAAAGGGGAGTAAAATATTAAGTGATATCAATGGTTAAC-3' (SEQ ID NO:
 59) 5'-TGGACGCGTGACGTCGACTCTAGAGGACCAATACTGAACCTATGA CC-3' (SEQ
 ID NO: 60) Plac + 38-nt 5'-
 CTGTATCCATATGACCATGATTACGGATTGGGCCCTTATATACTT spacer1 + GG-3'
 (SEQ ID NO: 61) terminator 5'-
 GCAAGAAAACGGTATATTTAAATACATCTCATGTTAAGGTTCAA
 CTTTCAGCCCTCCTGTGAAATTG-3' (SEQ ID NO: 62) 5'-
 CATGAGATGTATTTAAATATACCGTTTTCTTGCTCTCAC-3' (SEQ ID NO: 63) 5'-
 CTACAATAACACCCCTGAGGGTACCTGGAGATATAATAAGCT ATGCC-3' (SEQ ID
 NO: 64) Plac + 38-nt 5'-
 CCAACAAATTCAGAATTTATAGCTATGGTTGCATTTAAATACAT spacer2 +
 CTCATGTTAAGGTTCAACTTCAGCCCTCCTGTGAAATTG-3' (SEQ ID terminator NO:
 65) 5'-ATAGCTATAAATTCTGAATTTGTTGGTTTACCGTTGAACCTTAAC
 ATGAGATGTATTTAAATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 66) Para + 38-
 nt 5'-CTGTATCCATATGACCATGATTACGTTATGAAAGCGATTACCTA spacer1 + TAT-3'
 (SEQ ID NO: 67) terminator 5'-
 GCAAGAAAACGGTATATTTAAATACATCTCATGTTAAGGTTCAA
 CAATATTCCTCCTAAATTTATAATC-3' (SEQ ID NO: 68) Plac + 10-nt 5'-
 GGTTCAACAAAACGGTATATTTAAATACATCTCATGTTAAGGTT spacer1 +
 CAACTTCAGCCCTCCTGTG AAATTG-3' (SEQ ID NO: 69) terminator 5'-
 ATTTAAATATACCGTTTTGTTGAACCTTAACATGAGATGTATTTA
 AATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 70) Plac + 20-nt 5'-
 CAACTGAGAGCAAGAAAACGGTATATTTAAATACATCTCATGTT spacer1 +
 AAGGTTCAACTTCAGCCCT CCTGTGAAATTG-3' (SEQ ID NO: 71) terminator 5'-
 AAATATACCGTTTTCTTGCTCTCAGTTGAACCTTAACATGAGATG
 TATTTAAATCCCATAGAAG CTCTATACT-3' (SEQ ID NO: 72) Plac + 30-nt 5'-
 CTAATAGTAGTGAGAGCAAGAAAACGGTATATTTAAATACATCT spacer1 +
 CATGTTAAGGTTCAACTTC AGCCCTCCTGTGAAATTG-3' (SEQ ID terminator NO:
 73) 5'-ATACCGTTTTCTTGCTCTCACTACTATTAGGTTGAACCTTAACAT
 GAGATGTATTTAAATCCCA TAGAAGCTCTATACT-3' (SEQ ID NO: 74) Plac + 50-
 nt 5'-GATATAGCTAATAGTAGTGAGAGCAAGAAAACGGTATATTTAA spacer1 +
 ATACATCTCATGTTAAGGTTCAACTTCAGCCCTCCTGTGAAATTG-3' terminator (SEQ
 ID NO: 75) 5'-TTGCTCTCACTACTATTAGCTATATCATTATTAAACATTGTTGAA
 CCTTAACATGAGATGTATTTAAATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 76)
 spo0A and pyrF double deletion using endogenous Type I-BCRISPR-Cas system
 spo0A deletion 5'-CATGATTACGAATTCGAGCTCGGTACCCTCAAGGTATGAGTGG
 (arms, ~300 AAGTCC-3' (SEQ ID NO: 77) bp each) 5'-
 TGGACGCGTGACGTCGACTCTAGAGACATCTTCTATATATCTGC pyrF deletion
 AAAATAGCTTC-3' (SEQ ID NO: 78) (30-nt spacer) 5'-
 CCTGACTCTAGAGTCGACGTCACGCGTCGATTGGGCCCTTATAT ACTTGG-3' (SEQ
 ID NO: 79) 5'-AGGAGTATTTGTCCTTATAAGAACATCCAAATTTAAATACATCT

CATGTTAAGGTTTACAGCCCTCCTGTGAAATTG-3' (SEQ ID NO: 80) 5'-
 TTGGATGTTCTTATAAGGACAAATACTCCTGTTGAACCTTAACA
 TGAGATGTATTTAAATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 81) 5'-
 CGACGTTGTAAAACGACGGCCAGTGCCATGGAGATATAATAAG CTATGCC-3' (SEQ
 ID NO: 82) pyrF deletion 5'-
 CTGTATCCATATGACCATGATTACGGGCTATATTGGGTTTCATAGA (arms, ~300 TCC-3'
 (SEQ ID NO: 83) bp each) 5'-
 GCACACTCTGCATAGTCTGTGTAAGTATCCAGGCCTACACATAC-3' (SEQ ID NO:
 84) 5'-GTATGTGTAGGCCTGGATACTTACACAGACTATGCAGAGTGTGC-3' (SEQ ID
 NO: 85) 5'-TGGACGCGTGACGTCGACTCTAGAGTAGTTCCATTTCCAACCTAC CTG-3'
 (SEQ ID NO: 86) spo0A + pyrF 5'-
 CTGTATCCATATGACCATGATTACGCCCCGGGGATTGGGCCCTTA deletion TATACTTGG-3'
 (SEQ ID NO: 87) ((30 + 30) nt 5'-
 GGAGTATTTGTCCTTATAAGAACATCCAAATTTAAATACATCTC spacer)
 ATGTTAAGGTTCAACTTCAG CCCTCCTGTGAAATTG-3' (SEQ ID NO: 88) 5'-
 GGATGTTCTTATAAGGACAAATACTCCTGTTGAACCTTAACATG
 AGATGTATTTAAATATAACCG TTTTCTTGCTCTCAC-3' (SEQ ID NO: 89) 5'-
 CTACAACTAATACACCCTGAGGGTACCTGGAGATATAATAAGCT ATGCC-3' (SEQ ID
 NO: 90) spo0A + pyrF 5'-
 CATGATTACGAATTCGAGCTCGGTACCGCTATATTGGGTTTCAT deletion AGATCC-3'
 (SEQ ID NO: 91) ((~300 + ~300) 5'-
 GGACTTCCACTCATACCTTGAAGTAGTTCCATTTCCAACCTACCTG- bp arms) 3' (SEQ
 ID NO: 92) 5'-CAGGTAGTTGGAATGGAAGTAGTTCAAGGTATGAGTGGAAGT CC-
 3' (SEQ ID NO: 93) 5'-
 TGGACGCGTGACGTCGACTCTAGAGACATCTTCTATATATCTGC AAAATAGCTTC-3'
 (SEQ ID NO: 94) pta/ack deletion (or replaced by adhE1/adhE2) using
 endogenous Type I-B CRISPR-Cas system Plac + 34-nt 5'-
 CTGTATCCATATGACCATGATTACGGATTGGGCCCTTATATACTT spacer4 + GG-3'
 (SEQ ID NO: 95) terminator 5'-
 AGTATTAGGTACAGGATTTACAGCACAATCATTTAAATACATCT
 CATGTTAAGGTTCAACTTC AGCCCTCCTGTGAAATTG-3' (SEQ ID NO: 96) 5'-
 GTGCTGTAAATCCTGTACCTAATACTGAACGTTGAACCTTAACA
 TGAGATGTATTTAAATCCCATAGAAGCTCTATACT-3' (SEQ ID NO: 97) 5'-
 GTCGACTCTAGAGGATCCCCGGGTACCTGGAGATATAATAAGCT ATGCC-3' (SEQ
 ID NO: 98) Homology 5'-
 GGCATAGCTTATTATATCTCCAGGTACGTATCAACTACGCCTAA arms (~500 bp
 ATTCTCC-3' (SEQ ID NO: 99) each) 5'-
 TAGGCTGTTTACAGGGATCCCCGGGTACCTTTTCGTTTCTCCCTTCAA GAT-3' (SEQ ID
 NO: 100) 5'-GGAGAAACGAAAGGTACCCGGGGATCCCTGAACAGCCTATGGA AGACC-
 3' (SEQ ID NO: 101) 5'-
 TGGACGCGTGACGTCGACTCTAGAGCACCGTCAATTGCACATAC AC-3' (SEQ ID
 NO: 102) adhE1 5'-TATCTTGAAGGGAGAAACGAAAGGTACATGAAAGTCACAACAG
 TAAAGG-3' (SEQ ID NO: 103) 5'-
 TTATGGTCTTCCATAGGCTGTTTCAGGGTTGAAATATGAAGGTTT AAGGTTG-3' (SEQ
 ID NO: 104) adhE2 5'-TATCTTGAAGGGAGAAACGAAAGGTACATGAAAGTTACAAATC
 AAAAAG-3' (SEQ ID NO: 105) 5'-
 TTATGGTCTTCCATAGGCTGTTTCAGGGTTAAATGATTTTATATAG ATATCC-3' (SEQ
 ID NO: 106) cat1 deletion (or replaced by adhE1/adhE2) using endogenous
 Type I-B CRISPR-Cas system Plac + 34-nt 5'-
 CTGTATCCATATGACCATGATTACGGATTGGGCCCTTATATACTT spacer5 + GG-3'

(SEQ ID NO: 107) terminator 5'-
AGTTGTAGGGTTGATCCATCTTCTACAAGATTTAAATACATCTCA
TGTTAAGGTTCAACTTCAGCCCTCCTGTGAAATTG-3' (SEQ ID NO: 108) 5'-
GTAGAAGATGGATCAACCCTACAACCTTGGTAGTTGAACCTTAAC
ATGAGATGTATTTAAATCC CATAGAAGCTCTATACT-3' (SEQ ID NO: 109) 5'-
GTCGACTCTAGAGGATCCCCGGGTACCTGGAGATATAATAAGCTATGCC-3' (SEQ
ID NO: 110) Homology 5'-
GGCATAGCTTATTATATCTCCAGGTACACCCATGCTGCAAAGCA arms (~500 bp AGTT-
3' (SEQ ID NO: 111) each) 5'-
TGAGAAAGCTAAGGATCCCCGGGTACCAAAAACCACCCTTTCAT AAATT-3' (SEQ
ID NO: 112) 5'-GGGTGGTTTTTGGTACCCGGGGATCCTTAGCTTTCTCAAAGATA
TTTT-3' (SEQ ID NO: 113) 5'-
TGGACGCGTGACGTCGACTCTAGAGCCATATGCGGTGGTTATCAAC-3' (SEQ ID
NO: 114) adhE1 5'-AATTTATGAAAGGGTGGTTTTTGGTACATGAAAGTCACAACAGT
AAAGG-3' (SEQ ID NO: 115) 5'-
TTAAAAATATCTTTTGAGAAAGCTAAGGTTGAAATATGAAGGTT TAAGGTTG-3'
(SEQ ID NO: 116) adhE2 5'-
AATTTATGAAAGGGTGGTTTTTGGTACATGAAAGTTACAAATCAAAAAG-3' (SEQ
ID NO: 117) 5'-TTAAAAATATCTTTTGAGAAAGCTAAGTTAAATGATTTTATAT
AGATATCC-3' (SEQ ID NO: 118) Plasmid based adhE1/adhE2 overexpression
cat1 promoter 5'-CTGTATCCATATGACCATGATTACGGTAGACTTTAAGGATGGAA CC-
3' (SEQ ID NO: 119) 5'-
TCGACTCTAGAGGATCCCCGGGTACCGAATTCTGTGCGACTGCGA
TGAGCTAGGTCAGTAAAA ACCACCCTTTCATAAATT-3' (SEQ ID NO: 120) adhE1
5'-ATATAATTTATGAAAGGGTGGTTTTTATGAAAGTCACAACAGTAAAGG-3' (SEQ
ID NO: 121) 5'-CGACTCTAGAGGATCCCCGGGTACCGAATTCGTTGAAATATGAA
GGTTTAAGGTTG-3' (SEQ ID NO: 122) adhE2 5'-
ATATAATTTATGAAAGGGTGGTTTTTATGAAAGTTACAAATCAA AAAG-3' (SEQ ID
NO: 123) 5'-CGACTCTAGAGGATCCCCGGGTACCGGTAACCTTAAATGATTT
TATATAGATATCC-3' (SEQ ID NO: 124) Mutant detection spo0A deletion 5'-
TGTTCTGTAGGATCAGTATC-3' (SEQ ID NO: 125) 5'-
GGACTGTACCTCTGGTAGTTC-3' (SEQ ID NO: 126) pyrF deletion 5'-
GTTGAAAGACAGCTATATCTTGG-3' (SEQ ID NO: 127) 5'-
ATGCCATGTGATTCTCCATAG-3' (SEQ ID NO: 128) Pta-ack 5'-
TCTATACCTTCAGATACTTCTGG-3' (SEQ ID NO: 129) deletion 5'-
CTCACCTCTATACATTAGCCAC-3' (SEQ ID NO: 130) cat1 deletion 5'-
GCCATTAAGTACAAATGAGATAG-3' (SEQ ID NO: 131) 5'-
GCCATTAAGTACAAATGAGATAG-3' (SEQ ID NO: 132)

Discussion

(85) Within the past few years, CRISPR-Cas, the adaptive immune system from bacteria and archaea, has been repurposed for versatile genome editing and transcriptional regulation in various strain. However, so far, the majority of such applications are based on the Type II CRISPR-Cas9 system derived from *S. pyogenes*.

(86) Due to the unique feature of the chromosome of prokaryotic cells, the expression of the heterologous Cas9 is highly toxic, thus leading to poor transformation efficiency and failure of genome editing. Recently, the type V CRISPR-Cpf1 system has also been exploited for genome editing purposes. It has advantages over the CRISPR-Cas9 system due to its smaller size of the effector protein (Cpf1) and the more compact RNA guide (crRNA). Although the toxicity of Cpf1 is much lower than that of Cas9 as demonstrated in specific strains, remarkable decrease in transformation efficiency is still observed with the expression of Cpf1 in the host. Therefore, it is

challenging to carry out genome editing with CRISPR-Cas9/Cpf1 systems in microorganisms with low DNA transformation efficiencies.

(87) In this work, after many unsuccessful attempts for genome editing with the CRISPR-Cas9 or CRISPR-AsCpf1 systems, we successfully repurposed the Type I-B CRISPR-Cas system of *C. tyrobutyricum* as an efficient genome editing tool for this microorganism.

(88) In silico analysis of the CRISPR array in *C. tyrobutyricum* identified only one spacer sequence that can match protospacers from phage (prophage) of *Clostridium* and *Geobacillus* (FIG. 1B). However, we hypothesized that, due to the possible horizontal transferring property of CRISPR-Cas loci between closely-related strain, the Type I-B CRISPR-Cas systems from different *Clostridium* strain could be very similar and share similar/same PAMs and direct repeat sequences. Indeed, our subsequent in silico analysis demonstrated high homology between the CRISPR array in *C. tyrobutyricum* and that in *C. pasteurianum*. Therefore, the three PAM sequences from *C. pasteurianum* along with the putative PAMs identified in *C. tyrobutyricum* were employed to assess the activity of the endogenous CRISPR-Cas system of *C. tyrobutyricum*. The in vivo plasmid interference assay revealed that the Cas protein in *C. tyrobutyricum* had high affinity to the 5' adjacent PAM sequences TCA and TCG (FIG. 2B). These results verified our hypothesis that the Type I-B CRISPR-Cas system from *C. tyrobutyricum* shares the same PAM sequence (TCA) as that in *C. pasteurianum*, as well as those in *Clostridium tetani* and *C. thermocellum*.

(89) In attempt for the genome editing with the endogenous CRISPR-Cas system, initially, the native leader sequence was used as the promoter to drive the transcription of the synthetic CRISPR array. However, no transformants were obtained, likely due to the toxicity of the endogenous CRISPR-Cas system when it was instantly expressed. A lactose inducible promoter was employed to replace the leader sequence to drive the expression of the CRISPR-Cas system, resulting in an overall transformation efficiency of 1.7 CFU/mL donor (FIG. 3C). This transformation efficiency is still low, but is enough to enable us to obtain desirable mutants with a high editing efficiency. With this, we demonstrated that the inducible expression of the endogenous CRISPR-Cas array is achievable (although the configuration of the original native leader sequence for the CRISPR array regulation was complex) and effective to realize efficient genome editing in the host microorganism. It is also worthwhile to point out that, the same inducible promoter was also used to drive the expression of Cas9, nCas9 or AsCpf1 proteins to achieve genome editing for the same microorganism, however no successful transformation was achieved with any of the plasmids containing these heterologous nuclease (or nickase) proteins. This confirmed that the toxicity of the endogenous CRISPR-Cas system is much lower than that of heterologous CRISPR-Cas9/nCas9/AsCpf1 systems and thus more implementable for genome editing purposes (FIGS. 3B & 3C).

(90) Although the markerless genome engineering platform was developed, and high editing efficiency could be obtained, the transformation efficiency was still low which would restrict the application of the genome editing platform in *C. tyrobutyricum*. The length of spacers identified from the CRISPR Array1 and Array2 are not all the same (ranging from 34-38 nt). We reasoned that the length of the spacer might have an impact on the transformation efficiency and/or genome editing efficiency. Therefore, various lengths of spacers were systematically evaluated in the developed CRISPR-Cas system in the context for spo0A deletion. Results indicated that, the transformation was not successful when the spacer <20 nt was used, suggesting possible severe off-target effects (FIG. 3C). Spacers ranging from 30 to 50 nt can be used for targeting purposes for the successful genome editing. Comparatively, when shorter spacers were used, the genome editing efficiency was slightly decreased (for 30-nt spacer, an editing efficiency of 93.3% was obtained based on the large colonies), but meanwhile the transformation efficiency was dramatically enhanced (by approximately 500-fold for the 30-nt spacer). Therefore, depending on the different genome editing purposes, one can make a tradeoff between the transformation efficiency and genome editing efficiency by using a spacer of an appropriate length. Briefly, based on the above

results for the deletion of *spo0A* particularly, spacers of 30-38 nt seems good options. It should be pointed out that, one of the advantages with such an endogenous CRISPR-Cas system comparing to the type II CRISPR-Cas9 system for genome editing is that, the employment of the longer spacer sequence (30-38 nt vs. 20 nt for the spCRISPR-Cas9) can abate the potential off-target effect. Apparently, the longer the spacer sequence is, the more specific the targeting of the crRNA. For eukaryotic cells, the off-target effect can lead to unspecific mutations on the chromosome, which is highly problematic for various applications. This won't occur for the prokaryotic cells due to their inefficient endogenous nonhomologous end-joining (NHEJ) capability for the automatic DNA repairing. However, the off-target effect in prokaryotic cells can lead to cell death and thus failure of genome editing.

(91) In this study, multiplex genome editing was achieved by using the endogenous CRISPR-Cas system of *C. tyrobutyricum* (FIG. 4A). A synthetic CRISPR array carrying two spacers was used for the chromosome targeting to delete *spo0A* and *pyrF* simultaneously, yielding an editing efficiency of up to 100% (FIG. 4C). To date, this is the first success for multiplex genome editing in microorganisms with underdeveloped genome engineering tools such as *Clostridium*.

(92) *C. tyrobutyricum* is a natural hyper-butyrate producer, which has been engineered for butanol production previously. The *cat1* gene is believed to be the essential gene for butyrate production in *C. tyrobutyricum*, and the deletion of *cat1* was not previously achievable. In this study, based on the developed CRISPR-Cas genome engineering system, we successfully replaced the *cat1* gene with *adhE1/adhE2*. In this way, the butyrate production in *C. tyrobutyricum* was almost eliminated and the microorganism was converted into a hyper-butanol producer (FIG. 5). Previous studies have demonstrated that the lower temperature is beneficial to enhance the butanol tolerance of host strains, which may be because of the change of cell membrane composition and fluidity under lower temperatures. Therefore, fermentations for butanol production with the *C. tyrobutyricum* mutant were further carried out at lower temperatures. At 20° C., the butanol production in the mutant $\Delta cat1::adhE2$ reached 26.2 g/L in a regular batch fermentation. To the best of our knowledge, this is the highest butanol production that has ever been reported in a batch fermentation. We also investigated the butanol production of *C. beijerinckii* NCIMB 8052 and *C. saccharoperbutylacetonicum* N1-4 at lower temperatures (Table 5), to confirm whether carrying out fermentations at low temperatures is a broadly applicable mechanism to achieve high butanol production with other strains as well. Although the butanol production of these two solventogenic clostridia was increased at lower temperatures, the increment was far lower than that obtained with mutant $\Delta cat1::adhE2$, indicating that *C. tyrobutyricum* has much greater potential and thus is a more favorable host for butanol production. Furthermore, there is no acetone production in the fermentation of $\Delta cat1::adhE2$ as seen in the ABE fermentation; butanol, ethanol and acetate are the only primary end products. This on one hand simplifies the downstream recovery process; on the other, these end products could be further upgraded to high-value biochemicals (such as diesel, esters, etc.) through chemical or biochemical processes.

(93) TABLE-US-00008 TABLE 5 Summary of fermentation results for *C. beijerinckii* NCIMB 8052 and *C. saccharoperbutylacetonicum* N1-4 at various temperatures. sup.a

Strain	Temp (° C.)	Acetate (g/L)	Butyrate (g/L)	Acetone (g/L)	Ethanol (g/L)	Butanol (g/L)	Total ABE (g/L)
8052	35	0.10 ± 0.01	0.59 ± 0.04	5.70 ± 0.14	0.26 ± 0.02	9.68 ± 0.33	15.64
8052	30	0.13 ± 0.01	0.16 ± 0.05	6.31 ± 0.10	0.32 ± 0.03	9.96 ± 0.18	16.59
8052	25	0.39 ± 0.02	1.28 ± 0.13	3.33 ± 0.50	0.40 ± 0.03	9.71 ± 0.12	13.44
8052	20	0.22 ± 0.02	2.13 ± 0.13	3.75 ± 0.06	0.24 ± 0.01	11.12 ± 0.29	15.11
N1-4	30	0.94 ± 0.14	1.88 ± 0.28	5.89 ± 0.12	1.02 ± 0.15	17.10 ± 0.25	24.01
N1-4	25	1.23 ± 0.12	0.53 ± 0.05	4.21 ± 0.21	2.08 ± 0.04	18.07 ± 0.97	24.36
N1-4	20	0.41 ± 0.04	0.85 ± 0.08	4.10 ± 0.60	0.71 ± 0.01	18.09 ± 0.78	22.58

sup.a Values are based on at least two independent replicates.

Claims

1. A vector comprising a synthetic CRISPR array; an inducible promoter operably linked to said synthetic CRISPR array; and a first homology arm polylinker site; wherein said synthetic CRISPR array comprises a first direct repeat and a second direct repeat, wherein said first direct repeat and said second direct repeat have greater than 95% sequence identity to one another and are orientated relative to each other as direct repeats; and a first spacer polylinker site, wherein said first spacer polylinker site is located between said first direct repeat and said second direct repeat; and a CRISPR terminator sequence located after said second direct repeat.
2. The vector of claim 1 wherein said first direct repeat and said second direct repeat independently comprise a sequence having at least 95% sequence identity to SEQ ID NO: 2; and said CRISPR terminator sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO: 3.
3. The vector of claim 2 wherein the inducible promoter is a lactose inducible promoter.
4. The vector of claim 3 further comprising a native *Clostridium tyrobutyricum* Cas encoding sequence.
5. The vector of claim 4 wherein said native *Clostridium tyrobutyricum* Cas encoding sequence is operably linked to an inducible promoter.
6. The vector of claim 3 wherein a first spacer sequence of 20 to 50 nucleotides is inserted into said first spacer polylinker site; and a first homology arm sequence and a second homology arm sequence are inserted into said first homology arm polylinker site, wherein said first homology arm sequence comprises a nucleotide sequence sharing at least about 90% sequence identity to a first upstream sequence, and the second homology arm comprises a nucleotide sequence sharing at least about 90% sequence identity to a first downstream sequence.
7. A method of modifying a target site of a bacterial cell genome, said method comprising transforming said bacterial cell with the vector of claim 1 and selecting for transformants comprising said vector; inducing the expression of said synthetic CRISPR array; and identifying recombinant bacteria having a modification to said target site of the genome.
8. The method of claim 7 wherein the target site is the cat1 gene and the first spacer sequence comprises SEQ ID NO: 4.
9. The vector of claim 1, wherein said first direct repeat and said second direct repeat independently comprise a sequence having at least 95% sequence identity to SEQ ID NO: 2.
10. The vector of claim 1, wherein said CRISPR terminator sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO: 3.
11. The vector of claim 1, wherein said synthetic CRISPR array is a synthetic Type I-B CRISPR array.
12. The vector of claim 1, wherein the synthetic CRISPR array comprises a leader sequence comprising a sequence having at least 95% sequence identity to SEQ ID NO: 23.
13. The vector of claim 1, wherein said first direct repeat and said second direct repeat independently comprise a sequence having at least 95% sequence identity to SEQ ID NO: 2, wherein said CRISPR terminator sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO: 3, and wherein said synthetic CRISPR array is a synthetic Type I-B CRISPR array.
14. The vector of claim 1, wherein said first direct repeat and said second direct repeat independently comprise a sequence having at least 95% sequence identity to SEQ ID NO: 2, wherein said CRISPR terminator sequence comprises a sequence having at least 95% sequence identity to SEQ ID NO: 3, and wherein the synthetic CRISPR array comprises a leader sequence comprising a sequence having at least 95% sequence identity to SEQ ID NO: 23.
15. The vector of claim 1, wherein the first spacer polylinker site comprises a sequence having at least 95% sequence identity to SEQ ID NO: 9.

16. The vector of claim 1, wherein the first spacer polylinker site comprises a sequence having at least 95% sequence identity to SEQ ID NO: 4.
 17. The method of claim 7, wherein the target site of the bacterial cell genome comprises a gene encoding Spo0A.
 18. The method of claim 7, wherein the target site of the bacterial cell genome comprises a gene encoding a butyrate: acetate coenzyme A transferase.
-